<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychol Med</journal-id><journal-id journal-id-type="iso-abbrev">Psychol Med</journal-id><journal-id journal-id-type="publisher-id">PSM</journal-id><journal-title-group><journal-title>Psychological Medicine</journal-title></journal-title-group><issn pub-type="ppub">0033-2917</issn><issn pub-type="epub">1469-8978</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23237010</article-id><article-id pub-id-type="pmc">3642720</article-id><article-id pub-id-type="doi">10.1017/S0033291712002127</article-id><article-id pub-id-type="pii">S0033291712002127</article-id><article-id pub-id-type="publisher-id">00212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Cognitive remediation improves memory and psychosocial functioning in
first-episode psychiatric out-patients</article-title><alt-title alt-title-type="left-running">R. S. C. Lee et al.</alt-title><alt-title alt-title-type="right-running">Cognitive remediation as an early
intervention</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>R. S. C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Redoblado-Hodge</surname><given-names>M. A.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Naismith</surname><given-names>S. L.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hermens</surname><given-names>D. F.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Porter</surname><given-names>M. A.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hickie</surname><given-names>I. B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Clinical Research Unit</addr-line>,
<institution>Brain and Mind Research Institute, University of Sydney</institution>,
<addr-line>Sydney</addr-line>, <country>Australia</country></aff><aff id="aff2"><label>2</label><addr-line>Department of Psychology</addr-line>,
<institution>Macquarie University</institution>, <addr-line>Sydney</addr-line>,
<country>Australia</country></aff><aff id="aff3"><label>3</label><addr-line>Child Development Unit, The Children's Hospital at
Westmead, Sydney</addr-line>, <country>Australia</country></aff><author-notes><corresp id="cor1"><label>*</label><addr-line>Address for correspondence: Mr R. S. C. Lee,
100 Mallett Street</addr-line>, <institution>Brain and Mind Research
Institute</institution>, <addr-line>Camperdown, NSW 2050</addr-line>,
<country>Australia</country>. (Email: <email>sze.lee@sydney.edu.au</email>)</corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2012</year></pub-date><volume>43</volume><issue>6</issue><fpage>1161</fpage><lpage>1173</lpage><history><date date-type="received"><day>05</day><month>4</month><year>2012</year></date><date date-type="rev-recd"><day>27</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; Cambridge University Press 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Cambridge University Press</copyright-holder><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->The online version of this article is published within an Open Access
environment subject to the conditions of the Creative Commons
Attribution-NonCommercial-ShareAlike licence
&#x0003c;<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/2.5/">http://creativecommons.org/licenses/by-nc-sa/2.5/</ext-link>&#x0003e;. The written
permission of Cambridge University Press must be obtained for commercial
re-use.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="S0033291712002127a.pdf"/><abstract abstract-type="normal"><sec id="sec_a1"><title>Background</title><p>Cognitive remediation (CR) is an effective treatment for several psychiatric disorders.
To date, there have been no published studies examining solely first-episode psychiatric
cohorts, despite the merits demonstrated by early intervention CR studies. The current
study aimed to assess the effectiveness of CR in patients with a first-episode of either
major depression or psychosis.</p></sec><sec id="sec_a2" sec-type="methods"><title>Method</title><p>Fifty-five patients (mean age&#x000a0;=&#x000a0;22.8 years, <sc>s.d</sc>.&#x000a0;=&#x000a0;4.3) were randomly assigned
to either CR (<italic>n</italic>&#x000a0;=&#x000a0;28) or treatment as usual (TAU;
<italic>n</italic>&#x000a0;=&#x000a0;27). CR involved once-weekly 2-h sessions for a total of 10 weeks.
Patients were comprehensively assessed before and after treatment. Thirty-six patients
completed the study, and analyses were conducted using an intent-to-treat (ITT) approach
with all available data.</p></sec><sec id="sec_a3" sec-type="results"><title>Results</title><p>In comparison to TAU, CR was associated with improved immediate learning and memory
controlling for diagnosis and baseline differences. Similarly, CR patients demonstrated
greater improvements than TAU patients in psychosocial functioning irrespective of
diagnosis. Delayed learning and memory improvements mediated the effect of treatment on
psychosocial functioning at a marginal level.</p></sec><sec id="sec_a4" sec-type="conclusion"><title>Conclusions</title><p>CR improves memory and psychosocial outcome in first-episode psychiatric out-patients
for both depression and psychosis. Memory potentially mediated the functional gains
observed. Future studies need to build on the current findings in larger samples using
blinded allocation and should incorporate longitudinal follow-up and assessment of
potential moderators (e.g. social cognition, self-efficacy) to examine sustainability
and the precise mechanisms of CR effects respectively.</p></sec></abstract><kwd-group><title>Key words</title><kwd>Cognitive remediation</kwd><kwd>depression</kwd><kwd>early intervention</kwd><kwd>neuropsychology</kwd><kwd>psychosis</kwd></kwd-group><counts><fig-count count="2"/><table-count count="2"/><ref-count count="94"/><page-count count="13"/></counts></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Cognitive deficits are a clinically significant feature among psychiatric disorders and
often, in some combination, persist into remission (Millan <italic>et al.</italic>
<xref ref-type="bibr" rid="ref56">2012</xref>). In major depressive disorder (MDD; Jaeger
<italic>et al.</italic>
<xref ref-type="bibr" rid="ref33a">2006</xref>;Withall <italic>et al.</italic>
<xref ref-type="bibr" rid="ref86">2009</xref>) and schizophrenia (Green <italic>et al.</italic>
<xref ref-type="bibr" rid="ref27">2004</xref>), impairments are longitudinally predictive of
poor functional outcome. Furthermore, cognitive improvements following pharmacological
(Keefe <italic>et al.</italic>
<xref ref-type="bibr" rid="ref36">2007</xref>), neuropsychological (Fiszdon <italic>et al.</italic>
<xref ref-type="bibr" rid="ref20">2008</xref>) and psychosocial (Brekke <italic>et al.</italic>
<xref ref-type="bibr" rid="ref7">2009</xref>) interventions in schizophrenia are associated
with functional improvements, highlighting the potential that targeting neuropsychological
deficits has in reducing disability.</p><p>At present, psychiatric pharmacotherapies are largely ineffective in ameliorating
persisting cognitive deficits (Goldberg <italic>et al.</italic>
<xref ref-type="bibr" rid="ref25">2007</xref>). By contrast, cognitive rehabilitation seems
to be more promising. Initial studies used operant conditioning procedures in improving
behavioural performance (Cohen, <xref ref-type="bibr" rid="ref11">1956</xref>; Wagner, <xref ref-type="bibr" rid="ref82">1968</xref>). A second wave of studies in the early 1990s
brought together a range of techniques under the collective term &#x02018;cognitive remediation&#x02019;
(CR). CR programmes are highly heterogeneous, differing on whether they consist of
&#x02018;drill-and-practice&#x02019; or compensatory strategy learning, therapist facilitation, computer
training, or the length and intensity of treatment. Various structured programmes have
codified combinations of these approaches, including the Neuropsychological and Educational
Approach to Remediation (NEAR; Medalia <italic>et al.</italic>
<xref ref-type="bibr" rid="ref50">2002</xref>).</p><p>The efficacy of CR has been well established in chronic schizophrenia (Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref88">2011</xref>). Neuropsychological functioning seems to
benefit most from CR with mean effect sizes typically in the medium range (Medalia &#x00026;
Choi, <xref ref-type="bibr" rid="ref48">2009</xref>). Smaller effects are observed for
functional improvements, which are reported to be mediated by gains in memory and executive
functioning (Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref89">2007</xref>; Fiszdon <italic>et al.</italic>
<xref ref-type="bibr" rid="ref20">2008</xref>). Recently, CR has been successfully applied
to a range of other psychiatric disorders, including MDD (Elgamal <italic>et al.</italic>
<xref ref-type="bibr" rid="ref19">2007</xref>; Naismith <italic>et al.</italic>
<xref ref-type="bibr" rid="ref60">2010<italic>b</italic></xref>, <xref ref-type="bibr" rid="ref58">2011</xref>), bipolar disorder (Deckersbach <italic>et al.</italic>
<xref ref-type="bibr" rid="ref15">2010</xref>), anorexia nervosa (Wood <italic>et al.</italic>
<xref ref-type="bibr" rid="ref87">2011</xref>), obsessive&#x02013;compulsive disorder (Buhlmann
<italic>et al.</italic>
<xref ref-type="bibr" rid="ref8">2006</xref>) and substance use disorders (Bickel <italic>et
al.</italic>
<xref ref-type="bibr" rid="ref4">2011</xref>). Perhaps the basis for a potential
&#x02018;cross-diagnostic&#x02019; utility of CR is its focus on cognitive deficits readily found in
psychiatric illnesses. Indeed, a recent study found that CR effectiveness was unrelated to
diagnosis in schizophrenia-spectrum disorders (Lewandowski <italic>et al.</italic>
<xref ref-type="bibr" rid="ref41">2011</xref>). The enthusiasm for cross-diagnostic
implementation is reflected in studies using mixed psychiatric samples (Choi &#x00026;
Medalia, <xref ref-type="bibr" rid="ref10">2005</xref>; Naismith <italic>et al.</italic>
<xref ref-type="bibr" rid="ref59">2010<italic>a</italic></xref>). Pragmatically, a
cross-diagnostic implementation may prove to be more cost-effective in mental health clinics
that are not constrained by diagnostic groupings. Indeed, this approach is particularly
appropriate for younger patients in the early stages of psychiatric disease, where the
longitudinal trajectory is not yet evident (McGorry <italic>et al.</italic>
<xref ref-type="bibr" rid="ref47">2006</xref>; Hickie <italic>et al.</italic>
<xref ref-type="bibr" rid="ref31">2012</xref>).</p><p>CR studies have generally focused on later stages of psychiatric illness (cf. Wykes
<italic>et al.</italic>
<xref ref-type="bibr" rid="ref89">2007</xref>). By contrast, identification and treatment at
earlier stages are crucial, given the cumulative effects of mental disorders (McGorry
<italic>et al.</italic>
<xref ref-type="bibr" rid="ref47">2006</xref>; Hetrick <italic>et al.</italic>
<xref ref-type="bibr" rid="ref30">2008</xref>), which are underscored by findings that
longer durations of untreated illness are associated with structural brain abnormalities in
MDD (Sheline <italic>et al.</italic>
<xref ref-type="bibr" rid="ref73">2003</xref>) and schizophrenia (Lappin <italic>et al.</italic>
<xref ref-type="bibr" rid="ref37">2006</xref>; Malla <italic>et al.</italic>
<xref ref-type="bibr" rid="ref45">2011</xref>), and neuropsychological deterioration
(Amminger <italic>et al.</italic>
<xref ref-type="bibr" rid="ref2">2002</xref>; Lappin <italic>et al.</italic>
<xref ref-type="bibr" rid="ref38">2007</xref>; Gaynor <italic>et al.</italic>
<xref ref-type="bibr" rid="ref23">2009</xref>). Early intervention studies have largely
focused on pharmacological (Kahn <italic>et al.</italic>
<xref ref-type="bibr" rid="ref34">2008</xref>) and cognitive behavioural (Lynch <italic>et
al.</italic>
<xref ref-type="bibr" rid="ref43">2010</xref>) therapies, which typically affect
state-dependent cognitive function but have little effect on pre-existing or persisting
cognitive impairments. This is despite evidence demonstrating prominent memory deficits in
emerging MDD (Naismith <italic>et al.</italic>, unpublished observations) and prodromal
psychosis (Fusar-Poli <italic>et al.</italic>
<xref ref-type="bibr" rid="ref22">2012</xref>), and broader neuropsychological dysfunction
in first-episode MDD and schizophrenia across multiple cognitive domains (Mesholam-Gately
<italic>et al.</italic>
<xref ref-type="bibr" rid="ref53">2009</xref>; Lee <italic>et al.</italic>
<xref ref-type="bibr" rid="ref39">2012</xref>). Taken together with findings that
impairments seem to be related to higher rates of relapse and recurrence (Majer <italic>et
al.</italic>
<xref ref-type="bibr" rid="ref44">2004</xref>), the early treatment of persisting cognitive
impairment may prove to be an important step in reducing the everyday impact and chronicity
of mental disorders. To this end, several studies have demonstrated the effectiveness of CR
in improving neurocognition in early-onset adolescents with psychosis (Ueland &#x00026;
Rund, <xref ref-type="bibr" rid="ref78">2004</xref>, <xref ref-type="bibr" rid="ref79">2005</xref>; Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref89">2007</xref>), and also in combination with functional
gains and neuroprotection in &#x02018;early-course&#x02019; schizophrenia (Eack <italic>et al.</italic>
<xref ref-type="bibr" rid="ref17">2009</xref>, <xref ref-type="bibr" rid="ref18">2010</xref>). There are also two CR trials currently being conducted in first-episode
psychosis (Breitborde <italic>et al.</italic>
<xref ref-type="bibr" rid="ref6">2011</xref>; Vesterager <italic>et al.</italic>
<xref ref-type="bibr" rid="ref81">2011</xref>). To the best of our knowledge, there have
been no published studies demonstrating the effectiveness of CR in solely first-episode
psychiatric patients.</p><p>The paucity of early intervention studies is surprising given evidence suggesting that CR
programmes at earlier stages of schizophrenia (Gupta <italic>et al.</italic>
<xref ref-type="bibr" rid="ref28">2011</xref>) and at younger ages (Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref91">2009</xref>) are associated with greater cognitive and
functional gains. Conversely, CR at more chronic stages and older ages may yield poorer
outcomes (Dickinson <italic>et al.</italic>
<xref ref-type="bibr" rid="ref16">2010</xref>). Clearly, there is sufficient theoretical
impetus behind investigating CR in the early stages of major psychiatric illnesses. To this
end, the NEAR programme may be particularly well suited. NEAR uses both drill-and-practice
and compensatory approaches, and is based on theories of how people learn best (Medalia
&#x00026; Freilich, <xref ref-type="bibr" rid="ref49">2008</xref>). Principles such as
errorless learning, positive reinforcement and shaping help to guide therapists in promoting
behavioural change. Of particular relevance to early intervention, NEAR has been shown to be
effective in a mixed sample including first-episode schizophrenia patients (Redoblado-Hodge
<italic>et al.</italic>
<xref ref-type="bibr" rid="ref61">2010</xref>), and in a relatively young sample of MDD
patients (Naismith <italic>et al.</italic>
<xref ref-type="bibr" rid="ref60">2010<italic>b</italic></xref>). Additionally, a structured
psycho-education programme may be an important adjunct, and has recently been demonstrated
to be effective in late-life depression (Naismith <italic>et al.</italic>
<xref ref-type="bibr" rid="ref58">2011</xref>). Psycho-education is primarily aimed at
improving awareness of cognitive deficits, and is reported to improve insight in early
schizophrenia (Ruzanna <italic>et al.</italic>
<xref ref-type="bibr" rid="ref66">2010</xref>). Facilitating awareness is pivotal, given
that insight is commonly limited in both MDD (Yen <italic>et al.</italic>
<xref ref-type="bibr" rid="ref92">2005</xref>) and schizophrenia (Medalia &#x00026; Thysen,
<xref ref-type="bibr" rid="ref52">2008</xref>), with downstream effects on motivation
(Markland <italic>et al.</italic>
<xref ref-type="bibr" rid="ref46">2005</xref>), a crucial factor in CR success (Medalia
&#x00026; Saperstein, <xref ref-type="bibr" rid="ref51">2011</xref>). Indeed, it is also
difficult to see how patients would benefit from CR if they do not understand the reasons
for treatment and the precise cognitive functions being targeted.</p><p>Overall, the aim of the current study was to examine the clinical effectiveness of NEAR in
out-patients diagnosed with first-episode MDD or psychosis, two of the most common
presenting disorders in our youth mental health clinics (Scott <italic>et al.</italic>
<xref ref-type="bibr" rid="ref72">2009</xref>, <xref ref-type="bibr" rid="ref71">2012</xref>). These disorders were chosen on the basis that cognitive impairments are
common in both, and have been shown to respond to CR. Two primary hypotheses were
postulated. First, CR patients were expected to demonstrate greater gains in cognitive and
psychosocial functioning than a treatment-as-usual (TAU) cohort, which was included to
control for practice effects (Goldberg <italic>et al.</italic>
<xref ref-type="bibr" rid="ref26">2010</xref>) and the effects of ongoing psychosocial and
pharmacological treatment (Keefe <italic>et al.</italic>
<xref ref-type="bibr" rid="ref36">2007</xref>; Brekke <italic>et al.</italic>
<xref ref-type="bibr" rid="ref7">2009</xref>). Second, greater cognitive and functional
gains were expected in the CR group even while controlling for diagnosis to demonstrate the
cross-diagnostic utility of CR. A further aim of the current study was to determine whether
functional improvements would be mediated by improvement in memory and executive
functioning, consistent with the literature.</p></sec><sec sec-type="methods" id="sec2"><title>Method</title><sec id="sec2-1"><title>Subjects</title><p>The study was conducted at the Brain and Mind Research Institute (BMRI), Sydney,
Australia. Consecutive referrals were obtained from clinicians in affiliated out-patient
clinics (Headspace Central Sydney; The Clinical Centre, BMRI; Community Mental Health
Services, NSW Health). Patients were included if they met the following inclusion
criteria: (1) a lifetime history of a single episode of MDD or a psychotic disorder
according to DSM-IV-TR (APA, <xref ref-type="bibr" rid="ref3">2000</xref>); (2) clinically
stable as determined by a treating psychiatrist; and (3) fluent in English.</p><p>Participants were excluded if they: (i) were currently diagnosed with substance
dependence, a developmental disorder or a neurological condition; (ii) had a history of
traumatic brain injury; (iii) were currently prescribed a first-generation antipsychotic
medication; (iv) had an estimated pre-morbid intelligence quotient (IQ) of &#x0003c;80; or
(v) did not demonstrate significant cognitive dysfunction as defined by a
neuropsychological test score of at least 1.5 standard deviations (<sc>s.d</sc>.) below
their predicted pre-morbid IQ (Lezak <italic>et al.</italic>
<xref ref-type="bibr" rid="ref42">2012</xref>). This criterion was chosen to prevent
ceiling effects in the primary outcome measures, and from clinical experience, which has
demonstrated that most patients with severe mental illnesses meet this criteria. Indeed,
in a large sample of healthy adults, Schretlen <italic>et al.</italic> (<xref ref-type="bibr" rid="ref70">2003</xref>) found that the average person had at least one
neuropsychological test score falling 1.9 <sc>s.d</sc>. below their predicted pre-morbid
IQ, across a comprehensive neuropsychological battery not dissimilar from the current
study. Thus, including those with milder deficits may erroneously include patients not
cognitively impaired as a result of psychiatric morbidity, but normal intra-individual
variability.</p><p>Written informed consent was obtained from all participants. The current study was
approved by the Human Research Ethics Committees of the University of Sydney and Macquarie
University.</p></sec><sec id="sec2-2"><title>Design</title><p>Following referral and screening, participants were block randomized to either CR or TAU
(see <xref ref-type="fig" rid="fig01">Fig. 1</xref>). Neither clinicians (raters and
therapists) nor participants were blinded to allocation. Participants were initially
assessed on a range of measures, and subsequently commenced either a 10-week period of CR
while still receiving TAU or continued to receive TAU (only) for the same period. Patients
were reassessed using the same measures at follow-up. <fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Flowchart of study design.</p></caption><graphic xlink:href="S0033291712002127_fig1"/></fig></p></sec><sec id="sec2-3"><title>Measures</title><p>All participants were assessed by the first author (R.S.C.L.). At baseline, clinical and
demographic information was ascertained through an interview. Two measures were also
administered to estimate pre-morbid ability: the Wechsler Test of Adult Reading (WTAR;
Wechsler, <xref ref-type="bibr" rid="ref85">2001</xref>) and Information (Wechsler, <xref ref-type="bibr" rid="ref83">1997<italic>a</italic></xref>). Baseline and follow-up
assessments included clinical, neuropsychological and functional measures. Clinical
measures included the total score on the 17-item Hamilton Depression Rating Scale
(HAMD-17; Hamilton, <xref ref-type="bibr" rid="ref29">1960</xref>) and on the Brief
Psychiatric Rating Scale &#x02013; Expanded (BPRS-E; Ventura <italic>et al.</italic>
<xref ref-type="bibr" rid="ref80">1993</xref>). Primary outcomes included several
cognitive and functional measures. Neuropsychological tests were organized into five
theoretically derived cognitive domains (Lezak <italic>et al.</italic>
<xref ref-type="bibr" rid="ref42">2012</xref>). &#x02018;Processing Speed&#x02019; was measured using the
Trail Making Test &#x02013; Part A (TMT-A; Franzen <italic>et al.</italic>
<xref ref-type="bibr" rid="ref21">1990</xref>) and Category Fluency (Spreen &#x00026;
Benton, <xref ref-type="bibr" rid="ref74">1977</xref>). &#x02018;Attention and Working Memory&#x02019; was
assessed using Longest Digit Span Forward and Longest Digit Span Backward (LDSF and LDSB;
Wechsler, <xref ref-type="bibr" rid="ref83">1997<italic>a</italic></xref>), Spatial Span
length (Cambridge Neuropsychological Test Automated Battery, CANTAB; <uri xlink:type="simple" xlink:href="http://www.camcog.com">www.camcog.com</uri>), Rapid
Visual Processing Hits score (RVP Hits; CANTAB), and Mental Control (Wechsler, <xref ref-type="bibr" rid="ref84">1997<italic>b</italic></xref>). &#x02018;Immediate Learning and
Memory&#x02019; was measured using Logical Memory I (Wechsler, <xref ref-type="bibr" rid="ref84">1997<italic>b</italic></xref>), Rey Auditory Verbal Learning Test total score (RAVLT
Total; Taylor, <xref ref-type="bibr" rid="ref75">1959</xref>) and Paired Associates
Learning (PAL; CANTAB). &#x02018;Delayed Learning and Memory&#x02019; was assessed using Logical Memory II
Percentage Retention (LM Retention; Wechsler, <xref ref-type="bibr" rid="ref84">1997<italic>b</italic></xref>), RAVLT 20-Minute Percentage Retention (RAVLT
Retention; Taylor, <xref ref-type="bibr" rid="ref75">1959</xref>) and Rey&#x02013;Osterrieth
Complex Figure 3-Minute Recall (CFT 3min; Corwin &#x00026; Bylsma, <xref ref-type="bibr" rid="ref13">1993</xref>). &#x02018;Executive Functioning&#x02019; was indexed by TMT &#x02013; Part B (TMT-B;
Franzen <italic>et al.</italic>
<xref ref-type="bibr" rid="ref21">1990</xref>), Intra/Extradimensional Set Shift Errors
(IED Errors; CANTAB) and Letter Fluency (FAS; Spreen &#x00026; Benton, <xref ref-type="bibr" rid="ref74">1977</xref>). Alternate forms were used at follow-up where
available (Reitan &#x00026; Wolfson, <xref ref-type="bibr" rid="ref64">1985</xref>;
Crawford <italic>et al.</italic>
<xref ref-type="bibr" rid="ref14">1989</xref>; Hubley &#x00026; Tremblay, <xref ref-type="bibr" rid="ref33">2002</xref>). Scores were standardized into
<italic>z</italic> scores based on demographically adjusted norms from internal (Wechsler,
<xref ref-type="bibr" rid="ref83">1997<italic>a</italic></xref>, <xref ref-type="bibr" rid="ref84">b</xref>, CANTAB) and external samples (Meyers &#x00026; Meyers, <xref ref-type="bibr" rid="ref54">1995</xref>, <xref ref-type="bibr" rid="ref55">1996</xref>;
Tombaugh <italic>et al.</italic>
<xref ref-type="bibr" rid="ref77">1996</xref>, <xref ref-type="bibr" rid="ref76">1999</xref>; Rickert &#x00026; Senior, <xref ref-type="bibr" rid="ref65">1998</xref>).
Functional outcome was assessed using the standardized total score of the Social
Functioning Scale (SFS; mean&#x000a0;=&#x000a0;100, <sc>s.d</sc>.&#x000a0;=&#x000a0;15; Birchwood <italic>et al.</italic>
<xref ref-type="bibr" rid="ref5">1990</xref>). A higher score on neuropsychological and
functional measures indicated more superior functioning.</p></sec><sec id="sec2-4"><title>Intervention</title><p>The NEAR CR programme involved once-weekly 2-h sessions for a total of 10 weeks, and was
adapted to include a psycho-education component (Medalia &#x00026; Freilich, <xref ref-type="bibr" rid="ref49">2008</xref>). Each session started with psycho-education
regarding cognitive deficits and relevant compensatory strategies adapted from a
previously implemented programme in the elderly (Naismith <italic>et al.</italic>
<xref ref-type="bibr" rid="ref58">2011</xref>). Patients also received a bound workbook of
PowerPoint slides. The talks were given by either the therapist facilitating the groups
(R.S.C.L.) or invited guest speakers with expertise in the area of interest. Following
psycho-education, patients engaged in therapist-led drill-and-practice group activities,
and computer-assisted cognitive training using a range of software programs that were
educational, designed to target cognitive deficits in the laboratory and/or available
online. The cognitive training component was specifically tailored to each individual's
neuropsychological profile. Patients were encouraged throughout the program to experiment
with compensatory strategies during warm-up activities, computer training, and in their
own time outside the clinic.</p><p>All patients also received TAU care, involving ongoing monitoring by a psychiatrist of
symptoms and medication use, in addition to case management by mental health clinicians.
Participants were not concurrently involved in structured cognitive (e.g. social cognitive
remediation) or psychosocial (e.g. social skills training) rehabilitative interventions at
any time during the study.</p></sec><sec id="sec2-5"><title>Data analysis</title><p>IBM SPSS version 20.0 (SPSS Inc., USA) was used for all statistical analyses.
Neuropsychological standardized scores were reduced to five composite scores by averaging
<italic>z</italic> scores from each cognitive domain (Lezak <italic>et al.</italic>
<xref ref-type="bibr" rid="ref42">2012</xref>). Composite scores were used instead of
individual test scores because the latter are less reliable (Salthouse, <xref ref-type="bibr" rid="ref67">2012</xref>) and unnecessarily inflate the type I error
rate. Analyses were conducted using all available data excluding those from participants
who did not meet entry criteria. Thus, an intent-to-treat (ITT) approach was adopted,
assuming data were missing at random (MAR), including any significant predictors of
drop-out as covariates, consistent with previous research (Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref90">2012</xref>). One-way ANOVAs were conducted to
determine: (1) whether those who withdrew from the study were different from those who
completed the study; and (2) whether any baseline variable differed between treatment
conditions despite randomization. Any differences at baseline were also included as
covariates in subsequent and respective primary outcome analyses. Repeated-measures ANOVAs
were conducted on symptomatology (HAMD-17 and BPRS-E) and medication-use variables to
ensure primary outcome analyses were not confounded by symptom or medication change.
Primary outcomes were analysed using ANOVAs for each cognitive composite and psychosocial
functioning, with treatment condition as the between-subjects factor. Subsequently,
ANCOVAs were conducted to include any predictors of drop-out, baseline differences and
diagnosis as covariates. If functional change was significantly improved in CR compared to
TAU, it was regressed on treatment condition and each separate cognitive change score to
determine whether cognitive improvement predicted functional improvement over and above
the direct effects of treatment. For the primary cognitive outcomes based on Bonferroni
adjustments for multiple comparisons, &#x003b1; was set at 0.01. For all other statistical
inferences, &#x003b1; was set at 0.05.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><p>In total, 55 participants were recruited and assessed at baseline. Two participants were
excluded from further participation because of inadequate English or borderline impaired
pre-morbid IQ (&#x0003c;80). In addition, 17 participants dropped out prior to completing the
study because of hospitalization for relapse (<italic>n</italic>&#x000a0;=&#x000a0;3), work commitments
(<italic>n</italic>&#x000a0;=&#x000a0;3) or disinterest (<italic>n</italic>&#x000a0;=&#x000a0;11). In total, 36
participants completed the whole study, with seven and 11 first-episode depression and
psychosis patients in each condition respectively. There was no differential drop-out rate
between conditions (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05), and those who dropped out did not
differ from those who completed the study on any demographic or clinical variables,
medication use, neuropsychological or psychosocial functioning
(<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). The test&#x02013;retest interval averaged 21 and 19 weeks for CR
and TAU participants respectively (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05).</p><sec id="sec3-1"><title>Baseline differences</title><p>Baseline sample characteristics are displayed in <xref ref-type="table" rid="tab01">Table
1</xref>, and stratified according to treatment condition and diagnosis. Participants
were relatively young (mean age&#x000a0;=&#x000a0;22.8 years, <sc>s.d</sc>.&#x000a0;=&#x000a0;4.3, range 16&#x02013;34) and well
educated (mean&#x000a0;=&#x000a0;12.6 years, <sc>s.d</sc>.&#x000a0;=&#x000a0;2.1, range 9&#x02013;18). There were no significant
differences between treatment conditions on any baseline sample characteristics, including
the primary functional outcome (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). However, in terms of
diagnosis, first-episode psychosis patients had a significantly later age of onset
(<italic>F</italic><sub>1,47</sub>&#x000a0;=&#x000a0;7.08, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and lower
predicted IQ (<italic>F</italic><sub>1,50</sub>&#x000a0;=&#x000a0;6.33, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05),
were less depressed (<italic>F</italic><sub>1,51</sub>&#x000a0;=&#x000a0;8.23,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), had a greater proportion using medication (&#x003c7;<sup>2</sup>
<sub>1,53</sub>&#x000a0;=&#x000a0;12.07, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and antipsychotics (&#x003c7;<sup>2</sup>
<sub>1,53</sub>&#x000a0;=&#x000a0;27.65, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), and also a higher mean
haloperidol dose equivalency (<italic>F</italic><sub>1,37</sub>&#x000a0;=&#x000a0;11.04,
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01). <table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Sample characteristics of intent-to-treat (ITT) participants at baseline</p></caption><alternatives><graphic xlink:href="S0033291712002127_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">CR (<italic>n</italic>&#x000a0;=&#x000a0;26)</th><th rowspan="1" colspan="1">TAU (<italic>n</italic>&#x000a0;=&#x000a0;27)</th><th rowspan="1" colspan="1">Difference (<italic>F</italic>/&#x003c7;<sup>2</sup>)</th><th rowspan="1" colspan="1">First-episode depression (<italic>n</italic>&#x000a0;=&#x000a0;20)</th><th rowspan="1" colspan="1">First-episode psychosis (<italic>n</italic>&#x000a0;=&#x000a0;33)</th><th rowspan="1" colspan="1">Difference (<italic>F</italic>/&#x003c7;<sup>2</sup>)</th></tr></thead><tbody><tr><td rowspan="1" colspan="7">Sample</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Male: Female</td><td rowspan="1" colspan="1">12:14</td><td rowspan="1" colspan="1">16:11</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">8:12</td><td rowspan="1" colspan="1">20:13</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;First-episode depression</td><td rowspan="1" colspan="1">10 (38.5)</td><td rowspan="1" colspan="1">10 (37.0)</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;First-episode psychosis</td><td rowspan="1" colspan="1">16 (61.5)</td><td rowspan="1" colspan="1">17 (63.0)</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="7">Demographic characteristics</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Age (years)</td><td rowspan="1" colspan="1">22.88&#x000a0;&#x000b1;&#x000a0;4.0</td><td rowspan="1" colspan="1">22.74&#x000a0;&#x000b1;&#x000a0;4.7</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">22.00&#x000a0;&#x000b1;&#x000a0;4.9</td><td rowspan="1" colspan="1">23.30&#x000a0;&#x000b1;&#x000a0;3.9</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Age of onset (years)</td><td rowspan="1" colspan="1">19.00&#x000a0;&#x000b1;&#x000a0;3.9</td><td rowspan="1" colspan="1">18.08&#x000a0;&#x000b1;&#x000a0;4.7</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">16.41&#x000a0;&#x000b1;&#x000a0;2.9</td><td rowspan="1" colspan="1">19.66&#x000a0;&#x000b1;&#x000a0;4.5</td><td rowspan="1" colspan="1">7.08*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Years of education</td><td rowspan="1" colspan="1">12.46&#x000a0;&#x000b1;&#x000a0;1.8</td><td rowspan="1" colspan="1">12.63&#x000a0;&#x000b1;&#x000a0;2.3</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">12.45&#x000a0;&#x000b1;&#x000a0;1.7</td><td rowspan="1" colspan="1">12.61&#x000a0;&#x000b1;&#x000a0;2.3</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Predicted IQ<xref ref-type="table-fn" rid="tfn1_1">
<sup>a</sup>
</xref></td><td rowspan="1" colspan="1">100.85&#x000a0;&#x000b1;&#x000a0;9.4</td><td rowspan="1" colspan="1">104.31&#x000a0;&#x000b1;&#x000a0;7.0</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">106.10&#x000a0;&#x000b1;&#x000a0;7.1</td><td rowspan="1" colspan="1">100.38&#x000a0;&#x000b1;&#x000a0;8.5</td><td rowspan="1" colspan="1">6.33*</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;General knowledge (<italic>z</italic> score)<xref ref-type="table-fn" rid="tfn1_2">
<sup>b</sup>
</xref></td><td rowspan="1" colspan="1">0.58&#x000a0;&#x000b1;&#x000a0;1.0</td><td rowspan="1" colspan="1">0.81&#x000a0;&#x000b1;&#x000a0;0.8</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">0.93&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">0.56&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr><tr><td rowspan="1" colspan="7">Clinical characteristics</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;HAMD-17</td><td rowspan="1" colspan="1">10.65&#x000a0;&#x000b1;&#x000a0;6.4</td><td rowspan="1" colspan="1">8.59&#x000a0;&#x000b1;&#x000a0;6.6</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">12.70&#x000a0;&#x000b1;&#x000a0;7.5</td><td rowspan="1" colspan="1">7.73&#x000a0;&#x000b1;&#x000a0;5.1</td><td rowspan="1" colspan="1">8.23**</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;BPRS-E</td><td rowspan="1" colspan="1">37.35&#x000a0;&#x000b1;&#x000a0;7.6</td><td rowspan="1" colspan="1">35.70&#x000a0;&#x000b1;&#x000a0;10.4</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">35.55&#x000a0;&#x000b1;&#x000a0;7.6</td><td rowspan="1" colspan="1">37.09&#x000a0;&#x000b1;&#x000a0;9.9</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;SFS-Total</td><td rowspan="1" colspan="1">106.89&#x000a0;&#x000b1;&#x000a0;7.6</td><td rowspan="1" colspan="1">108.71&#x000a0;&#x000b1;&#x000a0;6.9</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">108.69&#x000a0;&#x000b1;&#x000a0;5.4</td><td rowspan="1" colspan="1">107.29&#x000a0;&#x000b1;&#x000a0;8.2</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr><tr><td rowspan="1" colspan="7">Medication use</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Medications</td><td rowspan="1" colspan="1">22 (84.6)</td><td rowspan="1" colspan="1">22 (81.5)</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">12 (60.0)</td><td rowspan="1" colspan="1">32 (97.0)</td><td rowspan="1" colspan="1">12.07***</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Antidepressants</td><td rowspan="1" colspan="1">10 (38.5)</td><td rowspan="1" colspan="1">10 (37.0)</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">9 (45.0)</td><td rowspan="1" colspan="1">11 (33.3)</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Antipsychotics</td><td rowspan="1" colspan="1">15 (57.7)</td><td rowspan="1" colspan="1">17 (63.0)</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">3 (15.0)</td><td rowspan="1" colspan="1">29 (87.9)</td><td rowspan="1" colspan="1">27.65***</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Haloperidol dose equivalence (mg)<xref ref-type="table-fn" rid="tfn1_3">
<sup>c</sup>
</xref></td><td rowspan="1" colspan="1">3.28&#x000a0;&#x000b1;&#x000a0;3.1</td><td rowspan="1" colspan="1">4.18&#x000a0;&#x000b1;&#x000a0;3.1</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">0.83&#x000a0;&#x000b1;&#x000a0;1.2</td><td rowspan="1" colspan="1">4.46&#x000a0;&#x000b1;&#x000a0;3.0</td><td rowspan="1" colspan="1">11.04**</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Benztropine dose equivalence (mg)<xref ref-type="table-fn" rid="tfn1_4">
<sup>d</sup>
</xref></td><td rowspan="1" colspan="1">4.35&#x000a0;&#x000b1;&#x000a0;14.6</td><td rowspan="1" colspan="1">4.50&#x000a0;&#x000b1;&#x000a0;15.4</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td><td rowspan="1" colspan="1">0.07&#x000a0;&#x000b1;&#x000a0;0.1</td><td rowspan="1" colspan="1">6.19&#x000a0;&#x000b1;&#x000a0;17.4</td><td rowspan="1" colspan="1"><sc>n.s</sc>.</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>CR, Cognitive remediation; TAU, treatment as usual; HAMD-17, 17-item Hamilton
Depression Rating Scale; BPRS-E, Brief Psychiatric Rating Scale &#x02013; Expanded; SFS,
Social Functioning Scale; <sc>n.s</sc>., not significant.</p></fn><fn><p>Values given as <italic>n</italic> (%) or mean &#x000b1; <sc>s.d</sc>.</p></fn><fn id="tfn1_1"><label>a</label><p>Wechsler (<xref ref-type="bibr" rid="ref85">2001</xref>) .</p></fn><fn id="tfn1_2"><label>b</label><p>Information subtest (Wechsler, <xref ref-type="bibr" rid="ref83">1997<italic>a</italic></xref>).</p></fn><fn id="tfn1_3"><label>c</label><p>Based on conversion table in Kane <italic>et al.</italic> (<xref ref-type="bibr" rid="ref35">2003</xref>) .</p></fn><fn id="tfn1_4"><label>d</label><p>Based on conversion table in Minzenberg <italic>et al.</italic> (<xref ref-type="bibr" rid="ref57">2004</xref>) .</p></fn><fn><p>*<italic>p</italic>&#x000a0;&#x02a7d;&#x000a0;0.05, **<italic>p</italic>&#x000a0;&#x02a7d;&#x000a0;0.01,
***<italic>p</italic>&#x000a0;&#x02a7d;&#x000a0;0.001.</p></fn></table-wrap-foot></table-wrap></p><p>CR participants also performed significantly worse than TAU participants in attention and
working memory at baseline (<italic>F</italic><sub>1,47</sub>&#x000a0;=&#x000a0;4.06,
<italic>p</italic>&#x000a0;=&#x000a0;0.05). No other cognitive domains were significantly different
between conditions (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). Diagnostically, first-episode
psychosis patients performed significantly more poorly than depressed patients on every
cognitive composite score (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.005; see <xref ref-type="fig" rid="fig02">Fig. 2</xref>). <fig id="fig02" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Neuropsychological profile (<italic>z</italic> scores and standard errors) of
cognitive composite scores according to diagnosis.</p></caption><graphic xlink:href="S0033291712002127_fig2"/></fig></p></sec><sec id="sec3-2"><title>Primary outcomes</title><p>There were no differential changes to psychiatric symptoms or medication dosage between
groups (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05), or changes to the type of medication(s)
prescribed between assessments.</p><p>Repeated-measures ANOVA for the primary cognitive composite scores indicated that CR
patients improved significantly more than TAU patients on attention and working memory
(<italic>F</italic><sub>1,34</sub>&#x000a0;=&#x000a0;8.10, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; see <xref ref-type="table" rid="tab02">Table 2</xref>) and immediate learning and memory
(<italic>F</italic><sub>1,34</sub>&#x000a0;=&#x000a0;15.51, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).
Controlling for diagnosis and baseline attention and working memory using
repeated-measures ANCOVA, only immediate learning and memory remained significant
(<italic>F</italic><sub>1,32</sub>&#x000a0;=&#x000a0;7.47, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01).
Specifically, CR independently contributed to 18.9% of the variance in immediate learning
and memory improvement, which is considered a relatively large effect according to Cohen's
criteria (<xref ref-type="bibr" rid="ref12">1988</xref>) . No other repeated-measures
ANCOVA interactions by group were significant (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05).
<table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Mean scores (&#x000b1; standard deviation) for each composite neuropsychological measure
and functional outcome stratified by treatment condition and time</p></caption><alternatives><graphic xlink:href="S0033291712002127_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="&#x000b1;" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="&#x000b1;" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="2" colspan="1" valign="bottom">Domain</th><th colspan="2" rowspan="1">Cognitive remediation (CR)</th><th colspan="2" rowspan="1">Treatment as usual (TAU)</th><th colspan="3" rowspan="1">Interaction<xref ref-type="table-fn" rid="tfn2_1">
<sup>a</sup>
</xref></th></tr><tr><th rowspan="1" colspan="1">Pre-CR</th><th rowspan="1" colspan="1">Post-CR</th><th rowspan="1" colspan="1">Pre-TAU</th><th rowspan="1" colspan="1">Post-TAU</th><th rowspan="1" colspan="1">
<italic>F</italic>
</th><th rowspan="1" colspan="1">
<italic>p</italic>
</th><th rowspan="1" colspan="1">Partial &#x003b7;<sup>2</sup></th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">Cognitive domain composite score</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Processing speed</td><td rowspan="1" colspan="1">&#x02212;0.16&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">0.06&#x000a0;&#x000b1;&#x000a0;0.8</td><td rowspan="1" colspan="1">0.26&#x000a0;&#x000b1;&#x000a0;0.8</td><td rowspan="1" colspan="1">0.12&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">0.42</td><td rowspan="1" colspan="1">0.52</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Attention and working memory</td><td rowspan="1" colspan="1">&#x02212;0.53&#x000a0;&#x000b1;&#x000a0;0.8</td><td rowspan="1" colspan="1">0.05&#x000a0;&#x000b1;&#x000a0;0.7</td><td rowspan="1" colspan="1">&#x02212;0.08&#x000a0;&#x000b1;&#x000a0;0.7</td><td rowspan="1" colspan="1">0.12&#x000a0;&#x000b1;&#x000a0;0.8</td><td rowspan="1" colspan="1">3.07</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Immediate learning and memory</td><td rowspan="1" colspan="1">&#x02212;0.76&#x000a0;&#x000b1;&#x000a0;1.1</td><td rowspan="1" colspan="1">&#x02212;0.18&#x000a0;&#x000b1;&#x000a0;1.0</td><td rowspan="1" colspan="1">&#x02212;0.41&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;0.44&#x000a0;&#x000b1;&#x000a0;1.1</td><td rowspan="1" colspan="1">7.47</td><td rowspan="1" colspan="1">0.01**</td><td rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Delayed learning and memory</td><td rowspan="1" colspan="1">&#x02212;0.84&#x000a0;&#x000b1;&#x000a0;1.1</td><td rowspan="1" colspan="1">&#x02212;0.40&#x000a0;&#x000b1;&#x000a0;1.1</td><td rowspan="1" colspan="1">&#x02212;0.66&#x000a0;&#x000b1;&#x000a0;0.8</td><td rowspan="1" colspan="1">&#x02212;0.54&#x000a0;&#x000b1;&#x000a0;1.2</td><td rowspan="1" colspan="1">0.38</td><td rowspan="1" colspan="1">0.54</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Executive functioning</td><td rowspan="1" colspan="1">&#x02212;0.56&#x000a0;&#x000b1;&#x000a0;1.0</td><td rowspan="1" colspan="1">&#x02212;0.39&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;0.32&#x000a0;&#x000b1;&#x000a0;0.7</td><td rowspan="1" colspan="1">&#x02212;0.31&#x000a0;&#x000b1;&#x000a0;0.8</td><td rowspan="1" colspan="1">0.00</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="1" colspan="8">Functional outcome</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Social Functioning Scale (SFS)</td><td rowspan="1" colspan="1">106.9&#x000a0;&#x000b1;&#x000a0;7.6</td><td rowspan="1" colspan="1">111.9&#x000a0;&#x000b1;&#x000a0;6.7</td><td rowspan="1" colspan="1">108.7&#x000a0;&#x000b1;&#x000a0;6.9</td><td rowspan="1" colspan="1">110.4&#x000a0;&#x000b1;&#x000a0;7.6</td><td rowspan="1" colspan="1">5.64</td><td rowspan="1" colspan="1">0.02*</td><td rowspan="1" colspan="1">0.15</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tfn2_1"><label>a</label><p>ANCOVA with diagnosis and baseline attention and working memory composite score
as covariates, or for functional outcome, ANCOVA with diagnosis as a
covariate.</p></fn><fn><p>*<italic>p</italic>&#x000a0;&#x02a7d;&#x000a0;0.05, **<italic>p</italic>&#x000a0;&#x02a7d;&#x000a0;0.01.</p></fn></table-wrap-foot></table-wrap></p><p>With regard to psychosocial functioning, controlling for diagnosis, CR patients
demonstrated significantly greater improvement than TAU patients on the SFS
(<italic>F</italic><sub>1,32</sub>&#x000a0;=&#x000a0;5.64, <italic>p</italic>&#x000a0;=&#x000a0;&#x0003c;&#x000a0;0.05). The
effect size of relative functional gain in CR patients was large, with treatment
accounting for 14.6% of the variability in improvement.</p></sec><sec id="sec3-3"><title>Mediation models</title><p>Controlling for the effects of treatment (&#x003b2;&#x000a0;=&#x000a0;0.30,
<italic>t</italic><sub>33</sub>&#x000a0;=&#x000a0;1.91, <italic>p</italic>&#x000a0;=&#x000a0;0.07), improvement in delayed
learning and memory independently predicted psychosocial gains at the trend level
(&#x003b2;&#x000a0;=&#x000a0;0.29, <italic>t</italic><sub>33</sub>&#x000a0;=&#x000a0;1.86, <italic>p</italic>&#x000a0;=&#x000a0;0.07). The overall
model was significant (<italic>R</italic><sup>2</sup>&#x000a0;=&#x000a0;0.21,
<italic>F</italic><sub>2,33</sub>&#x000a0;=&#x000a0;4.38, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). No other
changes to cognition were predictive of psychosocial improvement over and above
treatment.</p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Our results suggest that the neuropsychological profiles of patients recruited into the
current study were largely consistent with those seen in larger samples with similarly young
(Hermens <italic>et al.</italic>, unpublished observations) and first-episode
(Mesholam-Gately <italic>et al.</italic>
<xref ref-type="bibr" rid="ref53">2009</xref>; Lee <italic>et al.</italic>
<xref ref-type="bibr" rid="ref39">2012</xref>) cohorts. Pre-morbid intellectual functioning
and educational attainment in our sample were generally fairly high. Neuropsychological
functioning was most reduced in the learning and memory domains, consistent with studies
demonstrating verbal learning and memory as most impaired in average to high IQ
first-episode psychosis patients (Leeson <italic>et al.</italic>
<xref ref-type="bibr" rid="ref40">2011</xref>), and highly educated early-episode youth with
severe mental illnesses (Hermens <italic>et al.</italic>, unpublished observations). In
addition to memory, all other cognitive domains were significantly more reduced in patients
with psychosis compared to those with only depression, in keeping with the literature
(Schatzberg <italic>et al.</italic>
<xref ref-type="bibr" rid="ref68">2000</xref>). Overall, the current sample is
representative of those experiencing a first episode of MDD and psychosis.</p><p>The primary aim of the current study was to determine the effectiveness of CR as an early
intervention in first-episode depressive and psychotic disorders. A modified NEAR programme
was implemented in young out-patients, involving once-weekly cognitive training and
psycho-education groups for a total of 10 weeks. The results suggest that CR is effective in
improving immediate learning and memory. The effect size was large, and not inconsistent
with older MDD patients (Naismith <italic>et al.</italic>
<xref ref-type="bibr" rid="ref60">2010<italic>b</italic></xref>, <xref ref-type="bibr" rid="ref58">2011</xref>), and greater than those found previously in chronic schizophrenia
cohorts (Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref88">2011</xref>). The larger effects currently observed may be
suggestive of more favourable responses to neuropsychological intervention when implemented
in the early stages of mental illness. The results are also consistent with findings that
verbal learning and memory benefit most from CR in a young mixed psychiatric sample
(Naismith <italic>et al.</italic>
<xref ref-type="bibr" rid="ref59">2010<italic>a</italic></xref>).</p><p>Importantly, CR as an early intervention also seems to be effective in improving
psychosocial functioning. Effect size was again in the large range, and generally greater
than identified in previous studies in chronic schizophrenia (Medalia &#x00026; Choi, <xref ref-type="bibr" rid="ref48">2009</xref>), and contrary to findings in more chronic MDD
cohorts, which have largely failed to detect functional improvements (Naismith <italic>et
al.</italic>
<xref ref-type="bibr" rid="ref60">2010<italic>b</italic></xref>, <xref ref-type="bibr" rid="ref58">2011</xref>). This discrepancy may be again indicative of a better treatment
response when CR is implemented at earlier stages of mental illness.</p><p>Secondary to our primary outcome analyses, regression modelling suggested that improved
delayed learning and memory mediated the effect of CR on psychosocial improvements. The
overall model was significant and explained 21% of the variance in functional change. This
was found despite a non-significant primary outcome analysis for this domain, which may
suggest that the latter was underpowered, particularly given the inclusion of diagnosis and
baseline attention and working memory as covariates with the currently modest sample size.
The regression model is in keeping with previous findings demonstrating that functional
improvements are mediated by memory improvements (Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref89">2007</xref>; Fiszdon <italic>et al.</italic>
<xref ref-type="bibr" rid="ref20">2008</xref>), although executive functioning improvements
have also been shown to predict functional gains following CR (Reeder <italic>et al.</italic>
<xref ref-type="bibr" rid="ref62">2004</xref>, <xref ref-type="bibr" rid="ref63">2006</xref>; Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref90">2012</xref>). The failure to find a relationship between
executive functioning change and functional improvement was not entirely surprising given
that executive functioning did not respond to CR in the current study. Nonetheless, the
current results suggest that delayed learning and memory potentially mediates psychosocial
gains, although this requires further validation as our results were only significant at a
trend to marginal level, and cognitive functioning improvements may require more time to
generalize to real-world functioning.</p><p>In addition to neuropsychological functioning, several other mechanisms may explain social
and role functioning improvements attributable to CR. Social functioning improvements may be
mediated by aspects of social cognition, either wholly (Addington <italic>et al.</italic>
<xref ref-type="bibr" rid="ref1">2010</xref>; Schmidt <italic>et al.</italic>
<xref ref-type="bibr" rid="ref69">2011</xref>) or partly (Hoe <italic>et al.</italic>
<xref ref-type="bibr" rid="ref32">2012</xref>). Thus, cognitive functioning may be a
necessary, but insufficient, condition for functional improvement. With regard to role
functioning, self-efficacy, job opportunities and social networks, to name a few, may
moderate functional change over and above cognition. For instance, as a result of the
current CR treatment, participants' self-efficacy beliefs regarding their own abilities may
be strengthened in response to observed improvements on training tasks and, as a result,
stimulate their attempts to seek out employment or return to study. That is not to say that
cognitive functioning plays no part in role functioning. Indeed, it is difficult to imagine
how someone can hold down a moderately demanding job or area of study with clinically
significant cognitive impairments. Instead, cognitive improvements may influence role
functioning once a patient has returned to a higher level of functioning and is expected to
maintain those roles, consistent with evidence that neurocognition is associated with job
tenure, but not job attainment (Gold <italic>et al.</italic>
<xref ref-type="bibr" rid="ref24">2002</xref>). Thus, targeting self-efficacy may prove
crucial in improving occupational or academic functioning in the initial stages of illness
(Caprara <italic>et al.</italic>
<xref ref-type="bibr" rid="ref9">2004</xref>). Taken together, factors other than
neuropsychological functioning, such as social cognition and self-efficacy, may be crucial
rate-limiting factors in the translation of cognitive gains into the real world.
Furthermore, these factors could potentially account for a significant portion of the 79% of
functional improvement currently left unexplained.</p><p>The current study also demonstrated that cognitive and functional improvements were
detected even while controlling for the effects of diagnosis. This is consistent with
previous findings of CR's cross-diagnostic utility (Lewandowski <italic>et al.</italic>
<xref ref-type="bibr" rid="ref41">2011</xref>), and provides additional support for the need
to expand the application of CR into other psychiatric populations with demonstrable
neuropsychological dysfunction.</p><sec id="sec4-1"><title>Limitations and future directions</title><p>There were several limitations to the current study. The lack of blinded assessments may
have biased the clinical and neuropsychological results, although previous findings have
found negligible effects of methodological rigour on treatment effect (Wykes <italic>et
al.</italic>
<xref ref-type="bibr" rid="ref88">2011</xref>). Similarly, current practice in conducting
clinical trials favours the use of &#x02018;active&#x02019; controls over the use of &#x02018;passive&#x02019; controls.
The rationale is that the use of active controls can account for non-specific
therapist-related effects, such as demand characteristics. However, as with blindedness,
previous meta-analytic research has found minimal effect for control type on the effect
size of improvements (McGurk <italic>et al.</italic>
<xref ref-type="bibr" rid="ref47a">2007</xref>;Lewandowski <italic>et al.</italic>
<xref ref-type="bibr" rid="ref41">2011</xref>). Lastly, in terms of sample size, the
current study was also relatively modest and may have been underpowered to detect small to
moderate effects typical of CR studies. The sample size, however, was not incidental, and
is reflective of the difficulty in implementing a neuropsychological intervention in youth
cohorts, where engagement may be particularly difficult and drop-outs not uncommon. To
this end, future studies may benefit from incorporating motivational interviewing
techniques into CR programmes to help facilitate engagement and, as a result, adherence
(Markland <italic>et al.</italic>
<xref ref-type="bibr" rid="ref46">2005</xref>). Future studies should also examine the
factors that predict treatment response, which was not currently conducted because of the
restrictive sample size. The modest sample size also meant that more sophisticated
modelling of the relationships between neuropsychological variables and functional
improvements was not feasible (see Wykes <italic>et al.</italic>
<xref ref-type="bibr" rid="ref90">2012</xref> for an example of this type of
analysis).</p></sec><sec id="sec4-2"><title>Summary</title><p>The current study is the first to demonstrate the effectiveness of CR in clinically
stable out-patients diagnosed with a solely first episode of major depression or
psychosis. Improvements were detected in both immediate learning and memory and
psychosocial functioning. Improvements in delayed learning and memory contributed to
psychosocial gains at a trend level, over and above the functional benefits of treatment.
We propose that other factors, such as social cognition and self-efficacy, may also
mediate the effects between cognitive and functional gains, and should be further
explored. Future studies should also follow up patients longitudinally to determine the
baseline predictors of functional improvement, to allow enough time for cognitive gains to
translate into the real world, and to determine the durability of improvements. Despite
several limitations in the current study design, it provides evidence of the potential
that CR has as a potent early and targeted intervention strategy for those presenting with
severe mental illness. Future studies need to examine this cohort further under more
rigorously controlled conditions to provide more cogent evidence that CR should be
incorporated into the standard treatment of psychiatric illnesses.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank C. Chudleigh for help with facilitating treatment, K. Diamond for providing
resources and clinical supervision, and M. Kaur for her administrative assistance. We also
thank all the clinicians who made referrals to the current research programme without whom
the current study would not have been possible.</p><p>This research was supported by a National Health and Medical Research Council (NHMRC)
Program Grant (No. 350241) and an NHMRC Australia Fellowship awarded (No. 511921) to I.B.H.
S.LN. was funded by an NHMRC Clinical Research Fellowship (No. 402864).</p></ack><sec id="sec5"><title>Declaration of Interest</title><p>I.B.H. has led projects for health professionals and the community supported by
governmental, community agency, and drug industry partners (Wyeth, Eli Lilly, Servier,
Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has
served on advisory boards convened by the drug industry in relation to specific
antidepressants, including nefazodone, duloxetine, and desvenlafaxine, and has participated
in a multicenter clinical trial of agomelatine effects on sleep architecture in depression.
He has participated in Servier-sponsored educational programs related to circadian-based
therapies. D.F.H. has previously received honoraria for educational seminars from
Janssen-Cilag. M.A.R.H. has received financial support from Eli Lilly for a multisite trial
of cognitive remediation in psychosis, and is a co-investigator in an Australian
Rotary-funded project investigating the synergistic effects of cognitive remediation and
vocational training in psychosis. She was also a co-investigator in a drug trial with
Novartis Pharmaceutical who sponsored overseas travel in 2011, and was also involved in
NHMRC-funded trials in psychosis.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><name><surname>Addington</surname><given-names>J</given-names></name>, <name><surname>Girard</surname><given-names>TA</given-names></name>, <name><surname>Christensen</surname><given-names>BK</given-names></name>, <name><surname>Addington</surname><given-names>D</given-names></name> (<year>2010</year>). <article-title>Social cognition mediates illness-related and
cognitive influences on social function in patients with schizophrenia-spectrum
disorders</article-title>. <source>Journal of Psychiatry and Neuroscience</source><volume>35</volume>, <fpage>49</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="pmid">20040246</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><name><surname>Amminger</surname><given-names>G</given-names></name>, <name><surname>Edwards</surname><given-names>J</given-names></name>, <name><surname>Brewer</surname><given-names>W</given-names></name>, <name><surname>Harrigan</surname><given-names>S</given-names></name>, <name><surname>McGorry</surname><given-names>P</given-names></name> (<year>2002</year>). <article-title>Duration of untreated psychosis and cognitive
deterioration in first-episode schizophrenia</article-title>. <source>Schizophrenia
Research</source><volume>54</volume>, <fpage>223</fpage>&#x02013;<lpage>230</lpage><pub-id pub-id-type="pmid">11950547</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="book"><collab>APA</collab> (<year>2000</year>).
<source>Diagnostic and Statistical Manual of Mental Disorders</source>, <edition>4th
edn</edition>, text revision (DSM-IV-TR). <publisher-name>American Psychiatric
Association</publisher-name>: <publisher-loc>Washington,
DC</publisher-loc></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><name><surname>Bickel</surname><given-names>WK</given-names></name>, <name><surname>Yi</surname><given-names>R</given-names></name>, <name><surname>Landes</surname><given-names>RD</given-names></name>, <name><surname>Hill</surname><given-names>PF</given-names></name>, <name><surname>Baxter</surname><given-names>C</given-names></name> (<year>2011</year>). <article-title>Remember the future: working memory training
decreases delay discounting among stimulant addicts</article-title>. <source>Biological
Psychiatry</source><volume>69</volume>, <fpage>260</fpage>&#x02013;<lpage>265</lpage><pub-id pub-id-type="pmid">20965498</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><name><surname>Birchwood</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>J</given-names></name>, <name><surname>Cochrane</surname><given-names>R</given-names></name>, <name><surname>Wetton</surname><given-names>S</given-names></name>, <name><surname>Copestake</surname><given-names>S</given-names></name> (<year>1990</year>). <article-title>The Social Functioning Scale. The development
and validation of a new scale of social adjustment for use in family intervention
programmes with schizophrenic patients</article-title>. <source>British Journal of
Psychiatry</source><volume>157</volume>, <fpage>853</fpage>&#x02013;<lpage>859</lpage><pub-id pub-id-type="pmid">2289094</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><name><surname>Breitborde</surname><given-names>NJK</given-names></name>, <name><surname>Moreno</surname><given-names>FA</given-names></name>, <name><surname>Mai-Dixon</surname><given-names>N</given-names></name>, <name><surname>Peterson</surname><given-names>R</given-names></name>, <name><surname>Durst</surname><given-names>L</given-names></name>, <name><surname>Berstein</surname><given-names>B</given-names></name>, <name><surname>Byreddy</surname><given-names>S</given-names></name>, <name><surname>McFarlane</surname><given-names>WR</given-names></name> (<year>2011</year>). <article-title>Multifamily group psychoeducation and
cognitive remediation for first-episode psychosis: a randomized controlled
trial</article-title>. <source>BMC Psychiatry</source><volume>11</volume>, <fpage>9</fpage><pub-id pub-id-type="pmid">21226941</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><name><surname>Brekke</surname><given-names>JS</given-names></name>, <name><surname>Hoe</surname><given-names>M</given-names></name>, <name><surname>Green</surname><given-names>MF</given-names></name> (<year>2009</year>). <article-title>Neurocognitive change, functional change and
service intensity during community-based psychosocial rehabilitation for
schizophrenia</article-title>. <source>Psychological Medicine</source><volume>39</volume>, <fpage>1637</fpage>&#x02013;<lpage>1647</lpage><pub-id pub-id-type="pmid">19243648</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><name><surname>Buhlmann</surname><given-names>U</given-names></name>, <name><surname>Deckersbach</surname><given-names>T</given-names></name>, <name><surname>Engelhard</surname><given-names>I</given-names></name>, <name><surname>Cook</surname><given-names>LM</given-names></name>, <name><surname>Rauch</surname><given-names>SL</given-names></name>, <name><surname>Kathmann</surname><given-names>N</given-names></name>, <name><surname>Wilhelm</surname><given-names>S</given-names></name>, <name><surname>Savage</surname><given-names>CR</given-names></name> (<year>2006</year>). <article-title>Cognitive retraining for organizational
impairment in obsessive-compulsive disorder</article-title>. <source>Psychiatry Research</source><volume>144</volume>, <fpage>109</fpage>&#x02013;<lpage>116</lpage><pub-id pub-id-type="pmid">17007938</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><name><surname>Caprara</surname><given-names>GV</given-names></name>, <name><surname>Barbaranelli</surname><given-names>C</given-names></name>, <name><surname>Pastorelli</surname><given-names>C</given-names></name>, <name><surname>Cervone</surname><given-names>D</given-names></name> (<year>2004</year>). <article-title>The contribution of self-efficacy beliefs to
psychosocial outcomes in adolescence: predicting beyond global dispositional
tendencies</article-title>. <source>Personality and Individual Differences</source><volume>37</volume>, <fpage>751</fpage>&#x02013;<lpage>763</lpage></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>J</given-names></name>, <name><surname>Medalia</surname><given-names>A</given-names></name> (<year>2005</year>). <article-title>Factors associated with a positive response to
cognitive remediation in a community psychiatric sample</article-title>.
<source>Psychiatric Services</source><volume>56</volume>, <fpage>602</fpage>&#x02013;<lpage>604</lpage><pub-id pub-id-type="pmid">15872171</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>BD</given-names></name> (<year>1956</year>). <article-title>Motivation and performance in
schizophrenia</article-title>. <source>Journal of Abnormal and Social Psychology</source><volume>52</volume>, <fpage>186</fpage>&#x02013;<lpage>190</lpage></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="book"><name><surname>Cohen</surname><given-names>J</given-names></name> (<year>1988</year>). <source>Statistical Power Analysis for the Behavioral
Sciences</source>, <edition>2nd edn.</edition><publisher-name>Lawrence Erlbaum</publisher-name>: <publisher-loc>Mahwah,
NJ</publisher-loc></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><name><surname>Corwin</surname><given-names>J</given-names></name>, <name><surname>Bylsma</surname><given-names>FW</given-names></name> (<year>1993</year>). <article-title>Psychological examination of traumatic
encephalopathy</article-title>. <source>Clinical Neuropsychologist</source><volume>7</volume>, <fpage>3</fpage>&#x02013;<lpage>21</lpage></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><name><surname>Crawford</surname><given-names>JR</given-names></name>, <name><surname>Stewart</surname><given-names>LE</given-names></name>, <name><surname>Moore</surname><given-names>JW</given-names></name> (<year>1989</year>). <article-title>Demonstration of savings on the AVLT and
development of a parallel form</article-title>. <source>Journal of Clinical and
Experimental Neuropsychology</source><volume>11</volume>, <fpage>975</fpage>&#x02013;<lpage>981</lpage><pub-id pub-id-type="pmid">2592534</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><name><surname>Deckersbach</surname><given-names>T</given-names></name>, <name><surname>Nierenberg</surname><given-names>AA</given-names></name>, <name><surname>Kessler</surname><given-names>R</given-names></name>, <name><surname>Lund</surname><given-names>HG</given-names></name>, <name><surname>Ametrano</surname><given-names>RM</given-names></name>, <name><surname>Sachs</surname><given-names>G</given-names></name>, <name><surname>Rauch</surname><given-names>SL</given-names></name>, <name><surname>Dougherty</surname><given-names>D</given-names></name> (<year>2010</year>). <article-title>Cognitive rehabilitation for bipolar disorder:
an open trial for employed patients with residual depressive symptoms</article-title>.
<source>CNS Neuroscience and Therapeutics</source><volume>16</volume>, <fpage>298</fpage>&#x02013;<lpage>307</lpage><pub-id pub-id-type="pmid">19895584</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><name><surname>Dickinson</surname><given-names>D</given-names></name>, <name><surname>Tenhula</surname><given-names>W</given-names></name>, <name><surname>Morris</surname><given-names>S</given-names></name>, <name><surname>Brown</surname><given-names>C</given-names></name>, <name><surname>Peer</surname><given-names>J</given-names></name>, <name><surname>Spencer</surname><given-names>K</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Gold</surname><given-names>JM</given-names></name>, <name><surname>Bellack</surname><given-names>AS</given-names></name> (<year>2010</year>). <article-title>A randomized, controlled trial of
computer-assisted cognitive remediation for schizophrenia</article-title>.
<source>American Journal of Psychiatry</source><volume>167</volume>, <fpage>170</fpage>&#x02013;<lpage>180</lpage><pub-id pub-id-type="pmid">20008941</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><name><surname>Eack</surname><given-names>SM</given-names></name>, <name><surname>Greenwald</surname><given-names>DP</given-names></name>, <name><surname>Hogarty</surname><given-names>SS</given-names></name>, <name><surname>Cooley</surname><given-names>SJ</given-names></name>, <name><surname>DiBarry</surname><given-names>AL</given-names></name>, <name><surname>Montrose</surname><given-names>DM</given-names></name>, <name><surname>Keshavan</surname><given-names>MS</given-names></name> (<year>2009</year>). <article-title>Cognitive enhacement therapy for early-course
schizophrenia: effects of a two-year randomized controlled trial</article-title>.
<source>Psychiatric Services</source><volume>60</volume>, <fpage>1468</fpage>&#x02013;<lpage>1476</lpage><pub-id pub-id-type="pmid">19880464</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><name><surname>Eack</surname><given-names>SM</given-names></name>, <name><surname>Hogarty</surname><given-names>GE</given-names></name>, <name><surname>Cho</surname><given-names>RY</given-names></name>, <name><surname>Prasad</surname><given-names>KMR</given-names></name>, <name><surname>Greenwald</surname><given-names>DP</given-names></name>, <name><surname>Hogarty</surname><given-names>SS</given-names></name>, <name><surname>Keshavan</surname><given-names>MS</given-names></name> (<year>2010</year>). <article-title>Neuroprotective effects of cognitive
enhancement therapy against gray matter loss in early schizophrenia</article-title>.
<source>Archives of General Psychiatry</source><volume>67</volume>, <fpage>674</fpage>&#x02013;<lpage>682</lpage><pub-id pub-id-type="pmid">20439824</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><name><surname>Elgamal</surname><given-names>S</given-names></name>, <name><surname>Mckinnon</surname><given-names>MC</given-names></name>, <name><surname>Ramakrishnan</surname><given-names>K</given-names></name>, <name><surname>Joffe</surname><given-names>RT</given-names></name>, <name><surname>MacQueen</surname><given-names>G</given-names></name> (<year>2007</year>). <article-title>Successful computer-assisted cognitive
remediation therapy in patients with unipolar depression: a proof of principle
study</article-title>. <source>Psychological Medicine</source><volume>37</volume>, <fpage>1229</fpage>&#x02013;<lpage>1238</lpage><pub-id pub-id-type="pmid">17610766</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><name><surname>Fiszdon</surname><given-names>JM</given-names></name>, <name><surname>Choi</surname><given-names>J</given-names></name>, <name><surname>Goulet</surname><given-names>J</given-names></name>, <name><surname>Bell</surname><given-names>MD</given-names></name> (<year>2008</year>). <article-title>Temporal relationship between change in
cognition and change in functioning in schizophrenia</article-title>.
<source>Schizophrenia Research</source><volume>105</volume>, <fpage>105</fpage>&#x02013;<lpage>113</lpage><pub-id pub-id-type="pmid">18657398</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="other"><name><surname>Franzen</surname><given-names>MD</given-names></name>, <name><surname>Paul</surname><given-names>DS</given-names></name>, <name><surname>Price</surname><given-names>G</given-names></name> (<year>1990</year>). Alternate form reliability of Trails A, B, C, and D. Paper
presented at the Ninth Annual Convention of the National Academy of Neuropsychology, Reno,
NY.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><name><surname>Fusar-Poli</surname><given-names>P</given-names></name>, <name><surname>Deste</surname><given-names>G</given-names></name>, <name><surname>Smieskova</surname><given-names>R</given-names></name>, <name><surname>Barlati</surname><given-names>S</given-names></name>, <name><surname>Yung</surname><given-names>A</given-names></name>, <name><surname>Howes</surname><given-names>O</given-names></name>, <name><surname>Stieglitz</surname><given-names>R-D</given-names></name>, <name><surname>Vita</surname><given-names>A</given-names></name>, <name><surname>McGuire</surname><given-names>P</given-names></name>, <name><surname>Borgwardt</surname><given-names>S</given-names></name> (<year>2012</year>). <article-title>Cognitive functioning in prodromal psychosis:
a meta-analysis</article-title>. <source>Archives of General Psychiatry</source><volume>69</volume>, <fpage>562</fpage>&#x02013;<lpage>571</lpage><pub-id pub-id-type="pmid">22664547</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><name><surname>Gaynor</surname><given-names>K</given-names></name>, <name><surname>Dooley</surname><given-names>B</given-names></name>, <name><surname>Lawlor</surname><given-names>E</given-names></name>, <name><surname>Lawoyin</surname><given-names>L</given-names></name>, <name><surname>O'Callaghan</surname><given-names>E</given-names></name> (<year>2009</year>). <article-title>Cognitive deterioration and duration of
untreated psychosis</article-title>. <source>Early Intervention in Psychiatry</source><volume>3</volume>, <fpage>157</fpage>&#x02013;<lpage>160</lpage><pub-id pub-id-type="pmid">21352189</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><name><surname>Gold</surname><given-names>JM</given-names></name>, <name><surname>Goldberg</surname><given-names>RW</given-names></name>, <name><surname>McNary</surname><given-names>SW</given-names></name>, <name><surname>Dixon</surname><given-names>LB</given-names></name>, <name><surname>Lehman</surname><given-names>AF</given-names></name> (<year>2002</year>). <article-title>Cognitive correlates of job tenure among
patients with severe mental illness</article-title>. <source>American Journal of
Psychiatry</source><volume>159</volume>, <fpage>1395</fpage>&#x02013;<lpage>1402</lpage><pub-id pub-id-type="pmid">12153834</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><name><surname>Goldberg</surname><given-names>TE</given-names></name>, <name><surname>Goldman</surname><given-names>RS</given-names></name>, <name><surname>Burdick</surname><given-names>KE</given-names></name>, <name><surname>Malhotra</surname><given-names>AK</given-names></name>, <name><surname>Lencz</surname><given-names>T</given-names></name>, <name><surname>Patel</surname><given-names>RC</given-names></name>, <name><surname>Woerner</surname><given-names>MG</given-names></name>, <name><surname>Schooler</surname><given-names>NR</given-names></name>, <name><surname>Kane</surname><given-names>JM</given-names></name>, <name><surname>Robinson</surname><given-names>DG</given-names></name> (<year>2007</year>). <article-title>Cognitive improvement after treatment with
second-generation antipsychotic medications in first-episode schizophrenia: is it a
practice effect?</article-title><source>Archives of General Psychiatry</source><volume>64</volume>, <fpage>1115</fpage>&#x02013;<lpage>1122</lpage><pub-id pub-id-type="pmid">17909123</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><name><surname>Goldberg</surname><given-names>TE</given-names></name>, <name><surname>Keefe</surname><given-names>RSE</given-names></name>, <name><surname>Goldman</surname><given-names>RS</given-names></name>, <name><surname>Robinson</surname><given-names>DG</given-names></name>, <name><surname>Harvey</surname><given-names>PD</given-names></name> (<year>2010</year>). <article-title>Circumstances under which practice does not
make perfect: a review of the practice effect literature in schizophrenia and its
relevance to clinical treatment studies</article-title>. <source>Neuropsychopharmacology</source><volume>35</volume>, <fpage>1053</fpage>&#x02013;<lpage>1062</lpage><pub-id pub-id-type="pmid">20090669</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>MF</given-names></name>, <name><surname>Kern</surname><given-names>RS</given-names></name>, <name><surname>Heaton</surname><given-names>RK</given-names></name> (<year>2004</year>). <article-title>Longitudinal studies of cognition and
functional outcome in schizophrenia: implications for MATRICS</article-title>.
<source>Schizophrenia Research</source><volume>72</volume>, <fpage>41</fpage>&#x02013;<lpage>51</lpage><pub-id pub-id-type="pmid">15531406</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="book"><name><surname>Gupta</surname><given-names>M</given-names></name>, <name><surname>Holshausen</surname><given-names>K</given-names></name>, <name><surname>Bowie</surname><given-names>CR</given-names></name> (<year>2011</year>). <chapter-title>Cognitive remediation in early episode and
chronic outpatients with schizophrenia: who has more to gain?</chapter-title> In
<source>Cognitive Remediation in Psychiatry</source>, <publisher-loc>New York City,
NY</publisher-loc></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><name><surname>Hamilton</surname><given-names>M</given-names></name> (<year>1960</year>). <article-title>A rating scale for depression</article-title>.
<source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>23</volume>, <fpage>56</fpage>&#x02013;<lpage>62</lpage></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><name><surname>Hetrick</surname><given-names>SE</given-names></name>, <name><surname>Parker</surname><given-names>AG</given-names></name>, <name><surname>Hickie</surname><given-names>IB</given-names></name>, <name><surname>Purcell</surname><given-names>R</given-names></name>, <name><surname>Yung</surname><given-names>AR</given-names></name>, <name><surname>McGorry</surname><given-names>PD</given-names></name> (<year>2008</year>). <article-title>Early identification and intervention in
depressive disorders: towards a clinical staging model</article-title>.
<source>Psychotherapy and Psychosomatics</source><volume>77</volume>, <fpage>263</fpage>&#x02013;<lpage>270</lpage><pub-id pub-id-type="pmid">18560251</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><name><surname>Hickie</surname><given-names>I</given-names></name>, <name><surname>Scott</surname><given-names>E</given-names></name>, <name><surname>Hermens</surname><given-names>D</given-names></name>, <name><surname>Naismith</surname><given-names>S</given-names></name>, <name><surname>Guastella</surname><given-names>A</given-names></name>, <name><surname>Kaur</surname><given-names>M</given-names></name>, <name><surname>Sidis</surname><given-names>A</given-names></name>, <name><surname>Whitwell</surname><given-names>B</given-names></name>, <name><surname>Glozier</surname><given-names>N</given-names></name>, <name><surname>Davenport</surname><given-names>T</given-names></name>, <name><surname>Pantelis</surname><given-names>C</given-names></name>, <name><surname>Wood</surname><given-names>S</given-names></name>, <name><surname>McGorry</surname><given-names>P</given-names></name> (<year>2012</year>). <article-title>Applying clinical staging to young people who
present for mental health care</article-title>. <source>Early Intervention in
Psychiatry</source>. Published online: 05 06 2012. doi:<pub-id pub-id-type="doi">10.1111/j.1751-7893.2012.00366.x</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><name><surname>Hoe</surname><given-names>M</given-names></name>, <name><surname>Nakagami</surname><given-names>E</given-names></name>, <name><surname>Green</surname><given-names>MF</given-names></name>, <name><surname>Brekke</surname><given-names>JS</given-names></name> (<year>2012</year>). <article-title>The causal relationships between
neurocognition, social cognition and functional outcome over time in schizophrenia: a
latent difference score approach</article-title>. <source>Psychological
Medicine</source>. Published online: 05 04 2012. doi:<pub-id pub-id-type="doi">10.1017/S0033291712000578</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><name><surname>Hubley</surname><given-names>AM</given-names></name>, <name><surname>Tremblay</surname><given-names>D</given-names></name> (<year>2002</year>). <article-title>Comparability of total score performance on
the Rey-Osterrieth Complex Figure and a modified Taylor Complex Figure</article-title>.
<source>Journal of Clinical and Experimental Neuropsychology</source><volume>24</volume>, <fpage>370</fpage>&#x02013;<lpage>382</lpage><pub-id pub-id-type="pmid">11992218</pub-id></mixed-citation></ref><ref id="ref33a"><mixed-citation publication-type="journal"><name><surname>Jaeger</surname><given-names>J</given-names></name>, <name><surname>Berns</surname><given-names>S</given-names></name>, <name><surname>Uzelac</surname><given-names>S</given-names></name>, <name><surname>Davis-Conway</surname><given-names>S</given-names></name> (<year>2006</year>). <article-title>Neurocognitive deficits and disability in
major depressive disorder</article-title>. <source>Psychiatry Research</source><volume>145</volume>, <fpage>39</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="pmid">17045658</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><name><surname>Kahn</surname><given-names>RS</given-names></name>, <name><surname>Fleischhacker</surname><given-names>WW</given-names></name>, <name><surname>Boter</surname><given-names>H</given-names></name>, <name><surname>Davidson</surname><given-names>M</given-names></name>, <name><surname>Vergouwe</surname><given-names>Y</given-names></name>, <name><surname>Keet</surname><given-names>IPM</given-names></name>, <name><surname>Gheorghe</surname><given-names>MD</given-names></name>, <name><surname>Rybakowski</surname><given-names>JK</given-names></name>, <name><surname>Galderisi</surname><given-names>S</given-names></name>, <name><surname>Libiger</surname><given-names>J</given-names></name>, <name><surname>Hummer</surname><given-names>M</given-names></name>, <name><surname>Dollfus</surname><given-names>S</given-names></name>, <name><surname>Lopez-Ibor</surname><given-names>JJ</given-names></name>, <name><surname>Hranov</surname><given-names>LG</given-names></name>, <name><surname>Gaebel</surname><given-names>W</given-names></name>, <name><surname>Peuskens</surname><given-names>J</given-names></name>, <name><surname>Lindefors</surname><given-names>N</given-names></name>, <name><surname>Riecher-Rossler</surname><given-names>A</given-names></name>, <name><surname>Grobbee</surname><given-names>DE</given-names></name>; <collab>EUFEST study group</collab> (<year>2008</year>).
<article-title>Effectiveness of antipsychotic drugs in first-episode schizophrenia and
schizophreniform disorder: an open randomised clinical trial</article-title>.
<source>Lancet</source><volume>371</volume>, <fpage>1085</fpage>&#x02013;<lpage>1097</lpage><pub-id pub-id-type="pmid">18374841</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><name><surname>Kane</surname><given-names>JM</given-names></name>, <name><surname>Leucht</surname><given-names>S</given-names></name>, <name><surname>Carpenter</surname><given-names>D</given-names></name>, <name><surname>Docherty</surname><given-names>JP</given-names></name>; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic
Disorders (<year>2003</year>). <article-title>The expert consensus guideline series.
Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods,
commentary, and summary</article-title>. <source>Journal of Clinical Psychiatry</source><volume>64</volume> (<issue>Suppl. 12</issue>),
<fpage>5</fpage>&#x02013;<lpage>19</lpage><pub-id pub-id-type="pmid">14640142</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><name><surname>Keefe</surname><given-names>RSE</given-names></name>, <name><surname>Bilder</surname><given-names>RM</given-names></name>, <name><surname>Davis</surname><given-names>SM</given-names></name>, <name><surname>Harvey</surname><given-names>PD</given-names></name>, <name><surname>Palmer</surname><given-names>BW</given-names></name>, <name><surname>Gold</surname><given-names>JM</given-names></name>, <name><surname>Meltzer</surname><given-names>HY</given-names></name>, <name><surname>Green</surname><given-names>MF</given-names></name>, <name><surname>Capuano</surname><given-names>G</given-names></name>, <name><surname>Stroup</surname><given-names>TS</given-names></name>, <name><surname>McEvoy</surname><given-names>JP</given-names></name>, <name><surname>Swartz</surname><given-names>MS</given-names></name>, <name><surname>Rosenheck</surname><given-names>RA</given-names></name>, <name><surname>Perkins</surname><given-names>DO</given-names></name>, <name><surname>Davis</surname><given-names>CE</given-names></name>, <name><surname>Hsiao</surname><given-names>JK</given-names></name>, <name><surname>Lieberman</surname><given-names>JA</given-names></name>; <collab>CATIE Investigators</collab> (<year>2007</year>).
<article-title>Neurocognitive effects of antipsychotic medications in patients with
chronic schizophrenia in the CATIE trial</article-title>. <source>Archives of General
Psychiatry</source><volume>64</volume>, <fpage>633</fpage>&#x02013;<lpage>647</lpage><pub-id pub-id-type="pmid">17548746</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><name><surname>Lappin</surname><given-names>JM</given-names></name>, <name><surname>Morgan</surname><given-names>K</given-names></name>, <name><surname>Morgan</surname><given-names>C</given-names></name>, <name><surname>Hutchison</surname><given-names>G</given-names></name>, <name><surname>Chitnis</surname><given-names>X</given-names></name>, <name><surname>Suckling</surname><given-names>J</given-names></name>, <name><surname>Fearon</surname><given-names>P</given-names></name>, <name><surname>McGuire</surname><given-names>PK</given-names></name>, <name><surname>Jones</surname><given-names>PB</given-names></name>, <name><surname>Leff</surname><given-names>J</given-names></name>, <name><surname>Murray</surname><given-names>RM</given-names></name>, <name><surname>Dazzan</surname><given-names>P</given-names></name> (<year>2006</year>). <article-title>Gray matter abnormalities associated with
duration of untreated psychosis</article-title>. <source>Schizophrenia Research</source><volume>83</volume>, <fpage>145</fpage>&#x02013;<lpage>153</lpage><pub-id pub-id-type="pmid">16448803</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><name><surname>Lappin</surname><given-names>JM</given-names></name>, <name><surname>Morgan</surname><given-names>KD</given-names></name>, <name><surname>Morgan</surname><given-names>C</given-names></name>, <name><surname>Dazzan</surname><given-names>P</given-names></name>, <name><surname>Reichenberg</surname><given-names>A</given-names></name>, <name><surname>Zanelli</surname><given-names>JW</given-names></name>, <name><surname>Fearon</surname><given-names>P</given-names></name>, <name><surname>Jones</surname><given-names>PB</given-names></name>, <name><surname>Lloyd</surname><given-names>T</given-names></name>, <name><surname>Tarrant</surname><given-names>J</given-names></name>, <name><surname>Farrant</surname><given-names>A</given-names></name>, <name><surname>Leff</surname><given-names>J</given-names></name>, <name><surname>Murray</surname><given-names>RM</given-names></name> (<year>2007</year>). <article-title>Duration of untreated psychosis and
neuropsychological function in first episode psychosis</article-title>.
<source>Schizophrenia Research</source><volume>95</volume>, <fpage>103</fpage>&#x02013;<lpage>110</lpage><pub-id pub-id-type="pmid">17644343</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>RSC</given-names></name>, <name><surname>Hermens</surname><given-names>DF</given-names></name>, <name><surname>Porter</surname><given-names>MA</given-names></name>, <name><surname>Redoblado-Hodge</surname><given-names>MA</given-names></name> (<year>2012</year>). <article-title>A meta-analysis of cognitive deficits in
first-episode major depressive disorder</article-title>. <source>Journal of Affective
Disorders</source><volume>140</volume>, <fpage>113</fpage>&#x02013;<lpage>124</lpage><pub-id pub-id-type="pmid">22088608</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><name><surname>Leeson</surname><given-names>VC</given-names></name>, <name><surname>Sharma</surname><given-names>P</given-names></name>, <name><surname>Harrison</surname><given-names>M</given-names></name>, <name><surname>Ron</surname><given-names>MA</given-names></name>, <name><surname>Barnes</surname><given-names>TRE</given-names></name>, <name><surname>Joyce</surname><given-names>E</given-names></name> (<year>2011</year>). <article-title>IQ trajectory, cognitive reserve, and clinical
outcome following a first episode of psychosis: a 3-year longitudinal
study</article-title>. <source>Schizophrenia Bulletin</source><volume>37</volume>, <fpage>768</fpage>&#x02013;<lpage>777</lpage><pub-id pub-id-type="pmid">19934212</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><name><surname>Lewandowski</surname><given-names>KE</given-names></name>, <name><surname>Eack</surname><given-names>SM</given-names></name>, <name><surname>Hogarty</surname><given-names>SS</given-names></name>, <name><surname>Greenwald</surname><given-names>DP</given-names></name>, <name><surname>Keshavan</surname><given-names>MS</given-names></name> (<year>2011</year>). <article-title>Is cognitive enhancement therapy equally
effective for patients with schizophrenia and schizoaffective disorder?</article-title><source>Schizophrenia Research</source><volume>125</volume>, <fpage>291</fpage>&#x02013;<lpage>294</lpage><pub-id pub-id-type="pmid">21167689</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="book"><name><surname>Lezak</surname><given-names>MD</given-names></name>, <name><surname>Howieson</surname><given-names>DB</given-names></name>, <name><surname>Bigler</surname><given-names>ED</given-names></name>, <name><surname>Tranel</surname><given-names>E</given-names></name> (<year>2012</year>). <source>Neuropsychological Assessment</source>, <edition>5th
edn.</edition><publisher-name>Oxford University Press</publisher-name>: <publisher-loc>New
York</publisher-loc></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><name><surname>Lynch</surname><given-names>D</given-names></name>, <name><surname>Laws</surname><given-names>K</given-names></name>, <name><surname>McKenna</surname><given-names>P</given-names></name> (<year>2010</year>). <article-title>Cognitive behavioural therapy for major
psychiatric disorder: does it really work? A meta-analytical review of well-controlled
trials</article-title>. <source>Psychological Medicine</source><volume>40</volume>, <fpage>9</fpage>&#x02013;<lpage>24</lpage><pub-id pub-id-type="pmid">19476688</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><name><surname>Majer</surname><given-names>M</given-names></name>, <name><surname>Ising</surname><given-names>M</given-names></name>, <name><surname>Kunzel</surname><given-names>H</given-names></name>, <name><surname>Binder</surname><given-names>E</given-names></name>, <name><surname>Holsboer</surname><given-names>F</given-names></name>, <name><surname>Modell</surname><given-names>S</given-names></name>, <name><surname>Zihl</surname><given-names>J</given-names></name> (<year>2004</year>). <article-title>Impaired divided attention predicts delayed
response and risk to relapse in subjects with depressive disorders</article-title>.
<source>Psychological Medicine</source><volume>34</volume>, <fpage>1453</fpage>&#x02013;<lpage>1463</lpage><pub-id pub-id-type="pmid">15724876</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><name><surname>Malla</surname><given-names>AK</given-names></name>, <name><surname>Bodnar</surname><given-names>M</given-names></name>, <name><surname>Joober</surname><given-names>R</given-names></name>, <name><surname>Lepage</surname><given-names>M</given-names></name> (<year>2011</year>). <article-title>Duration of untreated psychosis is associated
with orbital-frontal grey matter volume reductions in first episode
psychosis</article-title>. <source>Schizophrenia Research</source><volume>125</volume>, <fpage>13</fpage>&#x02013;<lpage>20</lpage><pub-id pub-id-type="pmid">21059482</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><name><surname>Markland</surname><given-names>D</given-names></name>, <name><surname>Ryan</surname><given-names>RM</given-names></name>, <name><surname>Tobin</surname><given-names>VJ</given-names></name>, <name><surname>Rollnick</surname><given-names>S</given-names></name> (<year>2005</year>). <article-title>Motivational interviewing and
self-determination theory</article-title>. <source>Journal of Social and Clinical
Psychology</source><volume>24</volume>, <fpage>811</fpage>&#x02013;<lpage>831</lpage></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><name><surname>McGorry</surname><given-names>PD</given-names></name>, <name><surname>Hickie</surname><given-names>IB</given-names></name>, <name><surname>Yung</surname><given-names>AR</given-names></name>, <name><surname>Pantelis</surname><given-names>C</given-names></name>, <name><surname>Jackson</surname><given-names>HJ</given-names></name> (<year>2006</year>). <article-title>Clinical staging of psychiatric disorders: a
heuristic framework for choosing earlier, safer and more effective
interventions</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source><volume>40</volume>, <fpage>616</fpage>&#x02013;<lpage>622</lpage><pub-id pub-id-type="pmid">16866756</pub-id></mixed-citation></ref><ref id="ref47a"><mixed-citation publication-type="journal"><name><surname>McGurk</surname><given-names>PDS</given-names></name>, <name><surname>Twamley</surname><given-names>PDE</given-names></name>, <name><surname>Sitzer</surname><given-names>PDD</given-names></name>, <name><surname>McHugo</surname><given-names>PDG</given-names></name>, <name><surname>Mueser</surname><given-names>PDK</given-names></name> (<year>2007</year>). <article-title>A meta-analysis of cognitive remediation in
schizophrenia</article-title>. <source>American Journal of Psychiatry</source><volume>164</volume>, <fpage>1791</fpage>&#x02013;<lpage>1802</lpage><pub-id pub-id-type="pmid">18056233</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><name><surname>Medalia</surname><given-names>A</given-names></name>, <name><surname>Choi</surname><given-names>J</given-names></name> (<year>2009</year>). <article-title>Cognitive remediation in
schizophrenia</article-title>. <source>Neuropsychology Review</source><volume>19</volume>, <fpage>353</fpage>&#x02013;<lpage>364</lpage><pub-id pub-id-type="pmid">19444614</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><name><surname>Medalia</surname><given-names>A</given-names></name>, <name><surname>Freilich</surname><given-names>B</given-names></name> (<year>2008</year>). <article-title>The Neuropsychological Educational Approach to
Cognitive Remediation (NEAR) model: practice principles and outcome
studies</article-title>. <source>American Journal of Psychiatric Rehabilitation</source><volume>11</volume>, <fpage>123</fpage>&#x02013;<lpage>143</lpage></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="book"><name><surname>Medalia</surname><given-names>A</given-names></name>, <name><surname>Revheim</surname><given-names>N</given-names></name>, <name><surname>Herlands</surname><given-names>T</given-names></name> (<year>2002</year>). <source>Remediation of Cognitive Deficits in Psychiatric
Patients: A Clinician's Manual</source>. <publisher-name>Montefiore Medical Center
Press</publisher-name>: <publisher-loc>New York City, NY</publisher-loc></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><name><surname>Medalia</surname><given-names>A</given-names></name>, <name><surname>Saperstein</surname><given-names>A</given-names></name> (<year>2011</year>). <article-title>The role of motivation for treatment
success</article-title>. <source>Schizophrenia Bulletin</source><volume>37</volume>, <fpage>S122</fpage>&#x02013;<lpage>S128</lpage><pub-id pub-id-type="pmid">21860041</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><name><surname>Medalia</surname><given-names>A</given-names></name>, <name><surname>Thysen</surname><given-names>J</given-names></name> (<year>2008</year>). <article-title>Insight into neurocognitive dysfunction in
schizophrenia</article-title>. <source>Schizophrenia Bulletin</source><volume>34</volume>, <fpage>1221</fpage>&#x02013;<lpage>1230</lpage><pub-id pub-id-type="pmid">18199632</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><name><surname>Mesholam-Gately</surname><given-names>RI</given-names></name>, <name><surname>Giuliano</surname><given-names>AJ</given-names></name>, <name><surname>Goff</surname><given-names>KP</given-names></name>, <name><surname>Faraone</surname><given-names>SV</given-names></name>, <name><surname>Seidman</surname><given-names>LJ</given-names></name> (<year>2009</year>). <article-title>Neurocognition in first-episode schizophrenia:
a meta-analytic review</article-title>. <source>Neuropsychology</source><volume>23</volume>, <fpage>315</fpage>&#x02013;<lpage>336</lpage><pub-id pub-id-type="pmid">19413446</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="book"><name><surname>Meyers</surname><given-names>J</given-names></name>, <name><surname>Meyers</surname><given-names>K</given-names></name> (<year>1995</year>). <source>Rey Complex Figure Test and Recognition Trial:
Professional Manual</source>. <publisher-name>Psychological Assessment
Resources</publisher-name>: <publisher-loc>Odessa, FL</publisher-loc></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="book"><name><surname>Meyers</surname><given-names>J</given-names></name>, <name><surname>Meyers</surname><given-names>K</given-names></name> (<year>1996</year>). <source>Rey Complex Figure Test and Recognition Trial:
Supplemental Norms for Children and Adolescents</source>. <publisher-name>Psychological
Assessment Resources</publisher-name>: <publisher-loc>Odessa,
FL</publisher-loc></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><name><surname>Millan</surname><given-names>MJ</given-names></name>, <name><surname>Agid</surname><given-names>Y</given-names></name>, <name><surname>Br&#x000fc;ne</surname><given-names>M</given-names></name>, <name><surname>Bullmore</surname><given-names>ET</given-names></name>, <name><surname>Carter</surname><given-names>CS</given-names></name>, <name><surname>Clayton</surname><given-names>NS</given-names></name>, <name><surname>Connor</surname><given-names>R</given-names></name>, <name><surname>Davis</surname><given-names>S</given-names></name>, <name><surname>Deakin</surname><given-names>B</given-names></name>, <name><surname>DeRubeis</surname><given-names>RJ</given-names></name>, <name><surname>Dubois</surname><given-names>B</given-names></name>, <name><surname>Geyer</surname><given-names>MA</given-names></name>, <name><surname>Goodwin</surname><given-names>GM</given-names></name>, <name><surname>Gorwood</surname><given-names>P</given-names></name>, <name><surname>Jay</surname><given-names>TMJ</given-names></name>, <name><surname>Jo&#x000eb;ls</surname><given-names>M</given-names></name>, <name><surname>Mansuy</surname><given-names>IM</given-names></name>, <name><surname>Meyer-Lindenberg</surname><given-names>A</given-names></name>, <name><surname>Murphy</surname><given-names>D</given-names></name>, <name><surname>Rolls</surname><given-names>E</given-names></name>, <name><surname>Saletu</surname><given-names>B</given-names></name>, <name><surname>Spedding</surname><given-names>M</given-names></name>, <name><surname>Sweeney</surname><given-names>J</given-names></name>, <name><surname>Whittington</surname><given-names>M</given-names></name>, <name><surname>Young</surname><given-names>LJ</given-names></name> (<year>2012</year>). <article-title>Cognitive dysfunction in psychiatric
disorders: characteristics, causes and the quest for improved therapy</article-title>.
<source>Nature Reviews Drug Discovery</source><volume>11</volume>, <fpage>141</fpage>&#x02013;<lpage>168</lpage></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><name><surname>Minzenberg</surname><given-names>MJ</given-names></name>, <name><surname>Poole</surname><given-names>JH</given-names></name>, <name><surname>Benton</surname><given-names>C</given-names></name>, <name><surname>Vinogradov</surname><given-names>S</given-names></name> (<year>2004</year>). <article-title>Association of anticholinergic load with
impairment of complex attention and memory in schizophrenia</article-title>.
<source>American Journal of Psychiatry</source><volume>161</volume>, <fpage>116</fpage>&#x02013;<lpage>124</lpage><pub-id pub-id-type="pmid">14702259</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><name><surname>Naismith</surname><given-names>SL</given-names></name>, <name><surname>Diamond</surname><given-names>K</given-names></name>, <name><surname>Carter</surname><given-names>PE</given-names></name>, <name><surname>Norrie</surname><given-names>L</given-names></name>, <name><surname>Redoblado-Hodge</surname><given-names>MA</given-names></name>, <name><surname>Lewis</surname><given-names>SJG</given-names></name>, <name><surname>Hickie</surname><given-names>IB</given-names></name> (<year>2011</year>). <article-title>Enhancing memory in late-life depression: the
effects of a combined psychoeducation and cognitive training program</article-title>.
<source>American Journal of Geriatric Psychiatry</source><volume>19</volume>, <fpage>240</fpage>&#x02013;<lpage>248</lpage><pub-id pub-id-type="pmid">20808114</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><name><surname>Naismith</surname><given-names>SL</given-names></name>, <name><surname>Redoblado-Hodge</surname><given-names>MA</given-names></name>, <name><surname>Hermens</surname><given-names>DF</given-names></name>, <name><surname>Carter</surname><given-names>PE</given-names></name>, <name><surname>Scott</surname><given-names>EM</given-names></name>, <name><surname>Hickie</surname><given-names>IB</given-names></name> (<year>2010</year><italic>a</italic>). <article-title>Cognitive training improves
cognitive and psychosocial functioning in a mixed psychiatric outpatient
sample</article-title>. <source>Journal of Cognitive Rehabilitation</source><volume>28</volume>, <fpage>4</fpage>&#x02013;<lpage>10</lpage></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><name><surname>Naismith</surname><given-names>SL</given-names></name>, <name><surname>Redoblado-Hodge</surname><given-names>MA</given-names></name>, <name><surname>Lewis</surname><given-names>SJG</given-names></name>, <name><surname>Scott</surname><given-names>EM</given-names></name>, <name><surname>Hickie</surname><given-names>IB</given-names></name> (<year>2010</year><italic>b</italic>). <article-title>Cognitive training in
affective disorders improves memory: a preliminary study using the NEAR
approach</article-title>. <source>Journal of Affective Disorders</source><volume>121</volume>, <fpage>258</fpage>&#x02013;<lpage>262</lpage><pub-id pub-id-type="pmid">19616856</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><name><surname>Redoblado-Hodge</surname><given-names>MA</given-names></name>, <name><surname>Siciliano</surname><given-names>D</given-names></name>, <name><surname>Withey</surname><given-names>P</given-names></name>, <name><surname>Moss</surname><given-names>B</given-names></name>, <name><surname>Moore</surname><given-names>G</given-names></name>, <name><surname>Judd</surname><given-names>G</given-names></name>, <name><surname>Shores</surname><given-names>EA</given-names></name>, <name><surname>Harris</surname><given-names>A</given-names></name> (<year>2010</year>). <article-title>A randomized controlled trial of cognitive
remediation in schizophrenia</article-title>. <source>Schizophrenia Bulletin</source><volume>36</volume>, <fpage>419</fpage>&#x02013;<lpage>427</lpage><pub-id pub-id-type="pmid">18718884</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><name><surname>Reeder</surname><given-names>C</given-names></name>, <name><surname>Newtown</surname><given-names>E</given-names></name>, <name><surname>Frangou</surname><given-names>S</given-names></name>, <name><surname>Wykes</surname><given-names>T</given-names></name> (<year>2004</year>). <article-title>Which executive skills should we target to
affect social functioning and symptom change? A study of a cognitive remediation therapy
program</article-title>. <source>Schizophrenia Bulletin</source><volume>36</volume>, <fpage>87</fpage>&#x02013;<lpage>100</lpage><pub-id pub-id-type="pmid">15176764</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><name><surname>Reeder</surname><given-names>C</given-names></name>, <name><surname>Smedley</surname><given-names>N</given-names></name>, <name><surname>Butt</surname><given-names>K</given-names></name>, <name><surname>Bogner</surname><given-names>D</given-names></name>, <name><surname>Wykes</surname><given-names>T</given-names></name> (<year>2006</year>). <article-title>Cognitive predictors of social functioning
improvements following cognitive remediation for schizophrenia</article-title>.
<source>Schizophrenia Bulletin</source><volume>32</volume>, <fpage>S123</fpage>&#x02013;<lpage>S131</lpage><pub-id pub-id-type="pmid">16901950</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="book"><name><surname>Reitan</surname><given-names>RM</given-names></name>, <name><surname>Wolfson</surname><given-names>D</given-names></name> (<year>1985</year>). <source>The Halstead-Reitan Neuropsychological Test Battery:
Therapy and Clinical Interpretation</source>. <publisher-name>Neuropsychological
Press</publisher-name>: <publisher-loc>Tucson, AZ</publisher-loc></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="book"><name><surname>Rickert</surname><given-names>P</given-names></name>, <name><surname>Senior</surname><given-names>G</given-names></name> (<year>1998</year>). <chapter-title>WMS-III list learning test and the Rey
auditory verbal learning test: comparisons and Australian normative
data</chapter-title> In <source>4th Annual Conference of the College of Clinical
Neuropsychologists</source>, <publisher-name>Loren</publisher-name>,
<publisher-loc>Victoria, Australia</publisher-loc></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><name><surname>Ruzanna</surname><given-names>Z</given-names></name>, <name><surname>Marhani</surname><given-names>M</given-names></name>, <name><surname>Parveen</surname><given-names>K</given-names></name>, <name><surname>Cheah</surname><given-names>YC</given-names></name> (<year>2010</year>). <article-title>Does psychoeducation improve insight of
patients with schizophrenia?</article-title><source>Malaysian Journal of Psychiatry</source><volume>19</volume>, <fpage>27</fpage>&#x02013;<lpage>40</lpage></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><name><surname>Salthouse</surname><given-names>TA</given-names></name> (<year>2012</year>). <article-title>Robust cognitive change</article-title>.
<source>Journal of the International Neuropsychological Society</source><volume>18</volume>, <fpage>1</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">22152338</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><name><surname>Schatzberg</surname><given-names>AF</given-names></name>, <name><surname>Posener</surname><given-names>JA</given-names></name>, <name><surname>DeBattista</surname><given-names>C</given-names></name>, <name><surname>Kalehzan</surname><given-names>BM</given-names></name>, <name><surname>Rothschild</surname><given-names>AJ</given-names></name>, <name><surname>Shear</surname><given-names>PK</given-names></name> (<year>2000</year>). <article-title>Neuropsychological deficits in psychotic
versus nonpsychotic major depression and no mental illness</article-title>.
<source>American Journal of Psychiatry</source><volume>157</volume>, <fpage>1095</fpage>&#x02013;<lpage>1100</lpage><pub-id pub-id-type="pmid">10873917</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><name><surname>Schmidt</surname><given-names>SJ</given-names></name>, <name><surname>Mueller</surname><given-names>DR</given-names></name>, <name><surname>Roder</surname><given-names>V</given-names></name> (<year>2011</year>). <article-title>Social cognition as a mediator variable
between neurocognition and functional outcome in schizophrenia: empirical review and new
results by structural equation modeling</article-title>. <source>Schizophrenia Bulletin</source><volume>37</volume>, <fpage>S41</fpage>&#x02013;<lpage>S54</lpage><pub-id pub-id-type="pmid">21860046</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><name><surname>Schretlen</surname><given-names>DJ</given-names></name>, <name><surname>Munro</surname><given-names>CA</given-names></name>, <name><surname>Anthony</surname><given-names>JC</given-names></name>, <name><surname>Pearlson</surname><given-names>GD</given-names></name> (<year>2003</year>). <article-title>Examining the range of normal intraindividual
variability in neuropsychological test performance</article-title>. <source>Journal of
the International Neuropsychological Society</source><volume>9</volume>, <fpage>864</fpage>&#x02013;<lpage>870</lpage><pub-id pub-id-type="pmid">14632245</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>E</given-names></name>, <name><surname>Hermens</surname><given-names>D</given-names></name>, <name><surname>Glozier</surname><given-names>N</given-names></name>, <name><surname>Naismith</surname><given-names>S</given-names></name>, <name><surname>Guastella</surname><given-names>A</given-names></name>, <name><surname>Hickie</surname><given-names>I</given-names></name> (<year>2012</year>). <article-title>Targeted primary care-based mental health
services for young Australians</article-title>. <source>Medical Journal of Australia</source><volume>196</volume>, <fpage>136</fpage>&#x02013;<lpage>140</lpage><pub-id pub-id-type="pmid">22304610</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>E</given-names></name>, <name><surname>Naismith</surname><given-names>S</given-names></name>, <name><surname>Whitwell</surname><given-names>B</given-names></name>, <name><surname>Hamilton</surname><given-names>B</given-names></name>, <name><surname>Chudleigh</surname><given-names>C</given-names></name>, <name><surname>Hickie</surname><given-names>I</given-names></name> (<year>2009</year>). <article-title>Delivering youth-specific mental health
services: the advantages of a collaborative, multi-disciplinary system</article-title>.
<source>Australasian Psychiatry</source><volume>17</volume>, <fpage>189</fpage>&#x02013;<lpage>194</lpage><pub-id pub-id-type="pmid">19296265</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><name><surname>Sheline</surname><given-names>YI</given-names></name>, <name><surname>Gado</surname><given-names>MH</given-names></name>, <name><surname>Kraemer</surname><given-names>HC</given-names></name> (<year>2003</year>). <article-title>Untreated depression and hippocampal volume
loss</article-title>. <source>American Journal of Psychiatry</source><volume>160</volume>, <fpage>1516</fpage>&#x02013;<lpage>1518</lpage><pub-id pub-id-type="pmid">12900317</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="book"><name><surname>Spreen</surname><given-names>O</given-names></name>, <name><surname>Benton</surname><given-names>AL</given-names></name> (<year>1977</year>). <source>Neurosensory Center Comprehensive Examination for
Aphasia</source>. <publisher-name>Neuropsychology Laboratory, University of
Victoria</publisher-name>: <publisher-loc>Victoria, BC</publisher-loc></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="book"><name><surname>Taylor</surname><given-names>EM</given-names></name> (<year>1959</year>). <source>Psychological Appraisal of Children with Cerebral
Deficits</source>. <publisher-name>Harvard University Press</publisher-name>:
<publisher-loc>Cambridge, MA</publisher-loc></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><name><surname>Tombaugh</surname><given-names>TN</given-names></name>, <name><surname>Kozak</surname><given-names>J</given-names></name>, <name><surname>Rees</surname><given-names>L</given-names></name> (<year>1999</year>). <article-title>Normative data stratified by age and education
for two measures of verbal fluency: FAS and animal naming</article-title>.
<source>Archives of Clinical Neuropsychology</source><volume>14</volume>, <fpage>167</fpage>&#x02013;<lpage>177</lpage><pub-id pub-id-type="pmid">14590600</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="book"><name><surname>Tombaugh</surname><given-names>TN</given-names></name>, <name><surname>Rees</surname><given-names>L</given-names></name>, <name><surname>McIntyre</surname><given-names>N</given-names></name> (<year>1996</year>). <chapter-title>Normative data for the trail making
test</chapter-title> In <source>A Compendium of Neuropsychological Tests: Administration,
Norms and Commentary</source>, <edition>2nd edn</edition> (ed. <string-name>
<given-names>O.</given-names>
<surname>Spreen</surname>
</string-name> and <string-name>
<given-names>E.</given-names>
<surname>Strauss</surname>
</string-name>), p. <fpage>540</fpage>
<publisher-name>Oxford University
Press</publisher-name>: <publisher-loc>New York</publisher-loc></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Rund</surname><given-names>BR</given-names></name> (<year>2004</year>). <article-title>A controlled randomized treatment study: the
effects of a cognitive remediation program on adolescents with early onset
psychosis</article-title>. <source>Acta Psychiatrica Scandinavica</source><volume>109</volume>, <fpage>70</fpage>&#x02013;<lpage>74</lpage><pub-id pub-id-type="pmid">14674961</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Rund</surname><given-names>BR</given-names></name> (<year>2005</year>). <article-title>Cognitive remediation for adolescents with
early onset psychosis: a 1-year follow-up study</article-title>. <source>Acta
Psychiatrica Scandinavica</source><volume>111</volume>, <fpage>193</fpage>&#x02013;<lpage>201</lpage><pub-id pub-id-type="pmid">15701103</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><name><surname>Ventura</surname><given-names>J</given-names></name>, <name><surname>Green</surname><given-names>MF</given-names></name>, <name><surname>Shaner</surname><given-names>A</given-names></name>, <name><surname>Liberman</surname><given-names>RP</given-names></name> (<year>1993</year>). <article-title>Training and quality assurance with the Brief
Psychiatric Rating Scale: &#x02018;The drift busters&#x02019;</article-title>. <source>International
Journal of Methods in Psychiatric Research</source><volume>3</volume>, <fpage>221</fpage>&#x02013;<lpage>224</lpage></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><name><surname>Vesterager</surname><given-names>L</given-names></name>, <name><surname>Christensen</surname><given-names>T&#x000d8;</given-names></name>, <name><surname>Olsen</surname><given-names>BB</given-names></name>, <name><surname>Krarup</surname><given-names>G</given-names></name>, <name><surname>Forchhammer</surname><given-names>HB</given-names></name>, <name><surname>Melau</surname><given-names>M</given-names></name>, <name><surname>Gluud</surname><given-names>C</given-names></name>, <name><surname>Nordentoft</surname><given-names>M</given-names></name> (<year>2011</year>). <article-title>Cognitive training plus a comprehensive
psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for
patients with first-episode schizophrenia (the NEUROCOM trial): a study protocol for a
centrally randomised, observer-blinded multi-centre clinical trial</article-title>.
<source>Trials</source><volume>12</volume>, <fpage>35</fpage><pub-id pub-id-type="pmid">21306612</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>BR</given-names></name> (<year>1968</year>). <article-title>The training of attending and abstracting
responses in chronic schizophrenia</article-title>. <source>Journal of Experimental
Research in Personality</source><volume>3</volume>, <fpage>77</fpage>&#x02013;<lpage>88</lpage></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="book"><name><surname>Wechsler</surname><given-names>DS</given-names></name> (<year>1997</year><italic>a</italic>). <source>Wechsler Adult Intelligence Scale &#x02013;
Third Edition (WAIS-III)</source>. <publisher-name>The Psychological
Corporation</publisher-name>: <publisher-loc>San Antonio,
TX</publisher-loc></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="book"><name><surname>Wechsler</surname><given-names>DS</given-names></name> (<year>1997</year><italic>b</italic>). <source>Wechsler Memory Scale &#x02013; Third
Edition (WMS-III)</source>. <publisher-name>The Psychological
Corporation</publisher-name>: <publisher-loc>San Antonio,
TX</publisher-loc></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="book"><name><surname>Wechsler</surname><given-names>DS</given-names></name> (<year>2001</year>). <source>Wechsler Test of Adult Reading</source>.
<publisher-name>The Psychological Corporation</publisher-name>: <publisher-loc>San
Antonio, TX</publisher-loc></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal"><name><surname>Withall</surname><given-names>A</given-names></name>, <name><surname>Harris</surname><given-names>L</given-names></name>, <name><surname>Cumming</surname><given-names>S</given-names></name> (<year>2009</year>). <article-title>The relationship between cognitive function
and clinical and functional outcomes in major depressive disorder</article-title>.
<source>Psychological Medicine</source><volume>39</volume>, <fpage>393</fpage>&#x02013;<lpage>402</lpage><pub-id pub-id-type="pmid">18533056</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal"><name><surname>Wood</surname><given-names>L</given-names></name>, <name><surname>Al-Khairulla</surname><given-names>H</given-names></name>, <name><surname>Lask</surname><given-names>B</given-names></name> (<year>2011</year>). <article-title>Group cognitive remediation therapy for
adolescents with anorexia nervosa</article-title>. <source>Clinical Child Psychology and
Psychiatry</source><volume>16</volume>, <fpage>225</fpage>&#x02013;<lpage>231</lpage><pub-id pub-id-type="pmid">21571765</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal"><name><surname>Wykes</surname><given-names>T</given-names></name>, <name><surname>Huddy</surname><given-names>V</given-names></name>, <name><surname>Cellard</surname><given-names>C</given-names></name>, <name><surname>McGurk</surname><given-names>SR</given-names></name>, <name><surname>Czobor</surname><given-names>P</given-names></name> (<year>2011</year>). <article-title>A meta-analysis of cognitive remediation for
schizophrenia: methodology and effect sizes</article-title>. <source>American Journal of
Psychiatry</source><volume>168</volume>, <fpage>472</fpage>&#x02013;<lpage>485</lpage><pub-id pub-id-type="pmid">21406461</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal"><name><surname>Wykes</surname><given-names>T</given-names></name>, <name><surname>Newton</surname><given-names>E</given-names></name>, <name><surname>Landau</surname><given-names>S</given-names></name>, <name><surname>Rice</surname><given-names>C</given-names></name>, <name><surname>Thompson</surname><given-names>N</given-names></name>, <name><surname>Frangou</surname><given-names>S</given-names></name> (<year>2007</year>). <article-title>Cognitive remediation therapy (CRT) for young
early onset patients with schizophrenia: an exploratory randomized controlled
trial</article-title>. <source>Schizophrenia Research</source><volume>94</volume>, <fpage>221</fpage>&#x02013;<lpage>230</lpage><pub-id pub-id-type="pmid">17524620</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal"><name><surname>Wykes</surname><given-names>T</given-names></name>, <name><surname>Reeder</surname><given-names>C</given-names></name>, <name><surname>Huddy</surname><given-names>V</given-names></name>, <name><surname>Taylor</surname><given-names>R</given-names></name>, <name><surname>Wood</surname><given-names>H</given-names></name>, <name><surname>Ghirasim</surname><given-names>N</given-names></name>, <name><surname>Kontis</surname><given-names>D</given-names></name>, <name><surname>Landau</surname><given-names>S</given-names></name> (<year>2012</year>). <article-title>Developing models of how cognitive
improvements change functioning: mediation, moderation and moderated
mediation</article-title>. <source>Schizophrenia Research</source><volume>138</volume>, <fpage>88</fpage>&#x02013;<lpage>93</lpage><pub-id pub-id-type="pmid">22503640</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal"><name><surname>Wykes</surname><given-names>T</given-names></name>, <name><surname>Reeder</surname><given-names>C</given-names></name>, <name><surname>Landau</surname><given-names>S</given-names></name>, <name><surname>Matthiasson</surname><given-names>P</given-names></name>, <name><surname>Haworth</surname><given-names>E</given-names></name>, <name><surname>Hutchinson</surname><given-names>C</given-names></name> (<year>2009</year>). <article-title>Does age matter? Effects of cognitive
rehabilitation across the age span</article-title>. <source>Schizophrenia Research</source><volume>113</volume>, <fpage>252</fpage>&#x02013;<lpage>258</lpage><pub-id pub-id-type="pmid">19524409</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal"><name><surname>Yen</surname><given-names>C-F</given-names></name>, <name><surname>Chen</surname><given-names>C-C</given-names></name>, <name><surname>Lee</surname><given-names>Y</given-names></name>, <name><surname>Tang</surname><given-names>T-C</given-names></name>, <name><surname>Ko</surname><given-names>C-H</given-names></name>, <name><surname>Yen</surname><given-names>J-Y</given-names></name> (<year>2005</year>). <article-title>Insight and correlates among outpatients with
depressive disorders</article-title>. <source>Comprehensive Psychiatry</source><volume>46</volume>, <fpage>384</fpage>&#x02013;<lpage>389</lpage><pub-id pub-id-type="pmid">16122540</pub-id></mixed-citation></ref></ref-list></back></article>